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1.1 Biological aspects of tumours
The most fundamental properties of tumours are relatively autonomous growth and, 
for malignant tumours, invasion and metastasis. The rate of growth of a tumour has 
important clinical consequences, as it will determine for example the time from 
initiation to clinical symptoms, or how long after treatment the tumour will recur if the 
treatment is unsuccessful. Tumours usually begin as small aggregates of tumour 
cells, which exchange nutrients and waste products with their surroundings by 
simple diffusion (1,2). However, an increase in tumour size beyond ~1 mm requires 
the induction of vasculature, a process called angiogenesis (3-5). This restriction in 
size is caused by lack of nutrients and oxygen supply by diffusion. For example, in 
tissues the oxygen diffusion limit corresponds to a distance of 100-200 |um between 
the capillary and the cells (6,7).
Tumour vessels often display an abnormal architecture, characterised by collapsing 
or poorly differentiated, fragile and leaky vessels, which are frequently unable to 
meet the rapid growth of tumour cells (8-10). This may result in local hypoxia and 
necrosis. Two forms of hypoxia have been identified in tumours: diffusion limited or 
'chronic' hypoxia and perfusion limited or 'acute' hypoxia. Cells that are located 
relatively far away from a blood vessel may become chronically hypoxic because of 
the limited diffusion distance of oxygen (6). The second form of hypoxia is induced 
by transiently closing of blood vessels, resulting in local fluctuations of blood flow 
and oxygen supply (11,12). The combination of an inadequate vascular network and 
fluctuating tumour blood flow may lead to a combination of chronic and acute 
hypoxia in tumour cells.
Tissue oxygenation is the result of oxygen supply and the respiration rate of the 
cells. Oxygen consumption rates of tumours are in general intermediate between 
those of normal tissues with low metabolic rates and normal tissues with relatively 
high metabolic rates (10,13). Besides glucose oxidation, tumours may also feature 
aerobic glycolysis; the breakdown of glucose to lactic acid in the presence of oxygen
(14). A third mechanism of glucose turnover is the anaerobic glycolysis. Lactic acid 
production has long been considered a specific biochemical marker of malignancies, 
and although nowadays this specificity has been disproved, the increased capacity 
for glycolysis still remains a characteristic of tumours (2). In general, the metabolic 
profile of tumours differs from that of normal tissue as a result of many physiological 
and chemical factors, for example differences in rate of proliferation, availability of 
nutrients, accumulation of waste products, and pH.
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1.2 Tumour treatment
The three main modalities for the treatment of tumours are surgery, radiation 
therapy, and chemotherapy, either used as a single treatment or in a combined 
regimen. The earliest discussions of the surgical treatment of tumours are found in 
the Edwin Smith papyrus from the Egyptian Middle Kingdom (circa 1600 BC), and 
surgery still forms the mainstay of treatment in many solid tumours (15). Radiation 
therapy was applied for the treatment of malignant tumours not long after the 
discovery of x-rays by Wilhelm Roentgen in 1895 (16,17). However, it was also soon 
recognised that radiation produced adverse effects in normal tissues. Only in the 
1950s technological developments enabled large-scale application of radiotherapy. 
The introduction of chemotherapy in the fifth and sixth decades of the twentieth 
century has resulted in the development of therapeutic interventions for patients with 
several types of advanced solid tumours (18,19). Research in cancer drug discovery 
and development has provided approximately sixty approved products for the 
treatment of malignancies nowadays (20).
Radiotherapy is based on the interaction of ionising radiation with molecules in 
biological tissue. The absorption of radiation in tissues leads to the excitation and 
ionisation of atoms. This may result in breakage of chemical bonds and the 
formation of free radicals. The high reactivity of free radicals leads to a chain of 
reactions that can damage proteins, deoxynucleic acids, phospholipids and other 
macromolecules and thereby disrupt cellular functions and integrity. The most 
critical target for cell killing is the DNA of the cell (21). The extent of cellular damage 
following radiation exposure is dependent on several factors, including cellular 
repair of lesions, the stage of the cell proliferation cycle, and the radiobiological 
susceptibility of cells. The latter depends strongly on the presence or absence of 
various chemical compounds. In particular the presence of oxygen is believed to 
prolong the lifetime of free radicals of cellular H2O and to enhance permanent 
damage to the target molecules (22). Thus, a high level of oxygen in tumour tissue 
increases the sensitivity of a tumour to radiotherapy (23). Measurement of 
pretreatment oxygenation status has been shown to be predictive of radiation 
response in both head and neck tumours and tumours of the uterine cervix (24,25).
As well-oxygenated cells are more radiosensitive than hypoxic cells, increasing 
tumour oxygen levels may improve the efficacy of radiotherapy. This may be 
achieved by breathing high oxygen content gases like carbogen; a gas mixture 
consisting of 95% O2 and 5% CO2. In response to breathing different hyperoxic 
hypercapnic gas mixtures a reduction in the hypoxic fraction was found in hypoxic 
tumours (26). This was also shown in hypoxic marker studies, in which carbogen 
breathing reduced chronic hypoxia in laryngeal tumours (27). Improvement of 
tumour oxygenation and radiation response under hyperoxic conditions has been 
shown in several human tumours (28-30).
11
C h a p t e r  1
1.3 Head and neck tumours
Head and neck carcinomas are malignant tumours that may arise on all lining 
membranes of the upper aerodigestive tract. Most of these tumours are squamous 
cell carcinomas. In the Western world, head and neck cancers account for 3-10% of 
all new cancers each year (31,32). In many developing countries head and neck 
cancer is more common, and it is among the leading causes of cancer mortality 
worldwide (31). The ratio for occurrence in males versus females is about 4:1. 
Greatest risk factor in head and neck carcinogenesis is tobacco use (33). Alcohol 
produces a modest independent risk (34), and the effects of alcohol and tobacco 
seem to be synergistic (35,36).
Presenting symptoms, patterns of disease spread, and survival rates all vary by site 
of the primary tumour within the head-neck region. The main treatment options are 
surgery and radiation therapy (37,38). Especially in the case of laryngeal tumours, 
strategies are being developed to spare the functionality of the organ involved. 
These include sophisticated radiation methods, and combinations of radio- 
therapeutic, chemotherapeutic, and surgical methods (30,39,40). As tumours in the 
head-neck region may have variable blood flow and contain large hypoxic regions, 
radiosensitivity may be improved by increasing the tumour oxygen level (27,41). 
Head and neck tumours have shown an improved response to accelerated 
radiotherapy in combination with carbogen breathing and administration of 
nicotinamide (ARCON). This may be caused by improved tumour oxygenation, 
possibly intermediated by vascular effects. ARCON yielded actuarial 3 year local 
control rates of 80% for advanced larynx tumours, which is higher than any other 
report in the literature for this category of patients (30). Comparable results were 
obtained for other squamous cell carcinomas in the head-neck region (30).
1.4 M eningiomas
Meningiomas are tumours arising from meningothelial cells that form the external 
membranous covering of the brain. Although meningiomas are not strictly brain 
tumours they are usually classified as such, because they arise within the 
intracranial cavity and present with neurologic symptoms and signs (42). 
Meningiomas comprise about 15-20% of all intracranial tumours (42,43). The 
majority of these tumours is benign, 1-2% are malignant, and about 5-7% are 
atypical meningiomas (44). Several histologic variants exist, but only a few have 
prognostic importance. Meningiomas are considerably more frequent in women than 
in men, with a female to male ratio of about 2:1 (44,45).
Meningiomas occur primarily at the base of the skull and over the cerebral 
convexities. Symptoms and signs include increased intracranial pressure, cranial
12
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nerve palsy, and epilepsy (46). When treatment is necessary, surgery is the primary 
therapeutical option. However, meningiomas tend to recur, especially if total 
resection is impossible. Among tumours that are completely resected, 20% recur 
within 10 years (47), and more than 80% recur after partial resection (48). For this 
reason additional treatment options for meningiomas are considered. Recently, 
there has been an increased interest in stereotactic radiosurgery and radiotherapy 
for the treatment of meningiomas (49,50). Although in general there is a fair 
response to radiotherapy, sometimes higher doses of radiation are needed to 
improve control rates. However, radiation dose levels are limited to avoid radiation 
damage to the normal central nervous system, complicating optimal radiation 
treatment for meningiomas (43).
1.5 Oligodendrogliomas
The most common primary brain tumours are gliomas, which include both astrocytic 
and oligodendroglial tumours (45). Oligodendrogliomas arise from oligodendrocytes 
or their precursors and they are usually located in the cortex and white matter of the 
cerebral hemispheres. Oligodendroglial tumours occur in patients of all ages, with a 
peak incidence between 25 and 50 years, accounting for approximately 10% of all 
intracranial tumours in this age group (42,46). In the WHO tumour grading system 
oligodendrogliomas are divided into two categories, low grade and high grade, 
which is of both prognostic and therapeutic relevance (45).
The presenting symptoms of patients with oligodendrogliomas are due to the raised 
intracranial pressure and to local or general brain dysfunction. Surgical resection is 
the primary mode of treatment in symptomatic patients and those with progressive 
disease. Because oligodendrogliomas generally show an infiltrative growth pattern, 
surgical cure remains unlikely (46). Until recently, the identification of oligodendro­
gliomas among glial tumours did not have therapeutical consequences. However, in 
1988 it was recognised that malignant oligodendrogliomas are sensitive to 
chemotherapy (51). A regimen of procarbazine, lomustine, and vincristine resulted 
in a marked shrinkage of tumours, as shown by neuroimaging. Subsequent studies 
established the beneficial effect of chemotherapy of both high and low grade 
oligodendrogliomas and mixed oligoastrocytomas (52-54). Because of this unique 
chemosensitivity of oligodendrogliomas compared to other brain tumours, 
differential diagnosis of these tumours has become increasingly important.
1.6 Rationale and outline of this thesis
A powerful technique to investigate anatomy, physiology, and metabolism in 
humans is Magnetic Resonance (MR). MR imaging and MR spectroscopy allow us
13
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to study patients with tumours in a noninvasive way. The identification of a tumoural 
mass and the assessment of its size and vascularisation can be achieved with MR 
imaging, while MR spectroscopy can provide additional metabolic information for 
tumour classification, differential diagnosis, prognosis, and follow-up. In the context 
of tumour therapy for example, it is important to know how efficiently blood is 
providing oxygen, nutrients, and drugs to tumour tissue. Identification and 
characterisation of tumours may thus assist in prediction of treatment response and 
selection of the best therapeutical option. For this purpose, MR techniques have 
been used to investigate tumour physiology and metabolism in patients with 
tumours in the head-neck region, patients with oligodendrogliomas, and patients 
with meningiomas. These studies are described in this thesis.
The general principles of MR imaging and MR spectroscopy and their main 
applications as used in this thesis are summarised in chapter 2. The role of MR 
imaging to study the physiology of squamous cell carcinomas of the larynx is 
discussed in chapter 3. Tumour blood oxygenation and vascularisation are 
assessed to characterise these tumours and the potential clinical applications of the 
MR imaging techniques used are investigated.
One of the central MR methods for the assessment of human tumours is dynamic 
contrast enhanced MRI. Its diagnostic value has been shown in for example breast 
tumours, cervix tumours, and prostate carcinoma, both in tumour detection, 
identification, staging, and monitoring tumour treatment response. In chapter 4 a 
method is presented for the quantification of the dynamic MR contrast agent uptake. 
Using a pharmacokinetic model, this dynamic contrast enhanced MRI data can be 
interpreted in physiological terms like vascular permeability, blood flow, and blood 
volume. The MRI method and the data analysis are implemented in a clinical 
protocol and tested for reproducibility.
Besides tumour blood flow also tumour oxygenation is an important factor 
determining the outcome of cancer therapy, especially radiotherapy. Because 
carbogen breathing is a promising radiosensitiser for tumours in the head-neck 
region, tumour blood oxygenation and vascularisation were studied by MRI to map 
the physiological characteristics of these tumours and their response to 
hyperoxygenation. This may clarify the good response of head and neck tumours to 
ARCON therapy, and may allow prediction of treatment outcome for individual 
tumours. This study is presented in chapter 5.
A similar MRI study investigating the effects of hyperoxygenation is described in 
chapter 6 for meningiomas. The radiosensitivity of meningiomas may be improved 
by increasing tumour oxygen levels, which may be achieved by breathing a high 
oxygen content gas, similar to tumours in the head-neck region. The effects of 
breathing a hyperoxic hypercapnic gas mixture are investigated by several MRI
14
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techniques, to assess changes in tumour oxygenation and vascular function. This 
MRI protocol may allow optimisation of radiation schemes for patients with 
meningiomas.
In chapter 7 an MR spectroscopy study is described characterising brain tumours, in 
particular oligodendrogliomas. In general brain tumours are pathologically 
diagnosed by analysis of tumour tissue obtained invasively by biopsy. Both MR 
imaging and MR spectroscopy can be applied to characterise brain tumours in a 
noninvasive way and have been used extensively for this purpose. As 
oligodendroglial tumours cannot be distinguished easily from other brain tumours 
based on clinical presentation and MR imaging alone, MR spectroscopy may 
provide helpful additional information on the metabolic profile of these tumours. In 
this way, oligodendrogliomas are characterised to enable specific identification of 
these tumours, which may guide the treatment selection for these patients.
15
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M a g n e t ic  R e s o n a n c e
Mark Rijpkema
CHAPTER 2
2.1 A BRIEF HISTORICAL OVERVIEW
2.1.1 Magnetism
The record of the discovery in the Western world of the first magnetic material is a 
poem by Nicander of Colophon, described in a footnote in Historiae Naturalis 
XXXVII, the work of the Roman naturalist Pliny the Elder (23-79 AD) (1). Circa 1000 
BC, a shepherd by the name of Magnes was tending sheep on the slopes of Mount 
Ida in the Troad in Mysia (now Turkey). Suddenly, he found that his iron tipped 
crook and the tacks in his sandals were strongly drawn to the earth. He dug up the 
ground to find stones that we now refer to as lodestones (magnetite, a magnetic 
oxide of iron, Fe3O4). The unexplained nature of the magnetic attraction however 
has been exploited by story tellers for a long time, making it difficult to separate fact 
from fancy. Lodestones found their application in compasses in China and in the 
12th century this knowledge came to the Western world. Understanding of the 
phenomenon 'magnetism' however would not be achieved until many centuries later 
(1-3). Today magnetic materials are applied in everyday life. We even know that 
bacteria, certain birds, butterflies and other insects have a magnetic sense of 
direction (4,5).
2.1.2 Nuclear Magnetic Resonance
The phenomenon of Nuclear Magnetic Resonance (NMR) was demonstrated for the 
first time in 1946 independently by Felix Bloch et al and Edward Purcell et al (6,7). 
In 1952 they were awarded the Nobel prize for physics for their discovery. They 
found that the nuclei of certain atoms, when placed in a magnetic field, absorbed 
energy in the radiofrequency range and re-emitted this energy during the transition 
to their original state. The phenomenon was called NMR; nuclear because the 
nucleus of an atom was involved, magnetic because a magnetic field was required, 
and resonance because of the direct dependence of the magnetic field strength and 
the radiofrequency.
NMR developed quickly as a scientific discipline. Bloch introduced the concepts of 
relaxation times and introduced the so-called Bloch equations in 1946 to describe 
the NMR phenomenon (8). NMR was used for chemical and physical molecular 
analysis and rapidly progressed to become the most powerful non-destructive 
analytical method in chemistry. The first potential medical application of NMR was 
described by Raymond Damadian in 1971, who reported that the NMR water signal 
of malignant tumours and normal tissues were different (9).
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2.1.3 Magnetic Resonance Imaging
In late 1972, a prospective contributor to the British scientific journal Nature received 
a letter from the editor of the journal that read as follows (10): "With regret I am 
returning your manuscript which we feel is not of sufficiently wide significance for 
inclusion in Nature. This action should not in any way be regarded as an adverse 
criticism of your work, nor even an indication of editorial policies on studies in this 
field [...]" The paper submitted was very short and described a new imaging 
technique dubbed zeugmatography, a method that was derived from the NMR 
technique. The author of the paper was Paul Lauterbur. As he wanted his paper 
published in Nature he wrote back to the editor proposing to change the style of the 
paper to make the applications more clear. Finally, the paper was accepted and 
published in the March 1973 issue in Nature under the title (11) "Image formation by 
induced local interaction; examples employing magnetic resonance". From reading 
this title one would not think that a revolutionary idea in medical imaging was hidden 
behind it; the foundation of magnetic resonance imaging, MRI. (Note -- With the 
introduction of NMR to clinical imaging, the adjective nuclear was dropped.)
Soon after Lauterbur's experiments (on a water sample), images were produced 
from small objects such as onions and peppers. In 1975 Richard Ernst proposed 
magnetic resonance imaging using phase and frequency encoding, and the Fourier 
Transform (12). This method is the basis of the current MRI techniques. A few years 
later Damadian completed construction of the first whole body scanner, which he 
dubbed Indomitable. July 3, 1977, Damadian made the first human MRI scan, which 
took almost 5 hours (13).
2.2 Basic concepts of Magnetic Resonance*
2.2.1 Spin , precession, and resonance
The secret of NMR* resides in the nucleus of an atom. Certain nuclei possess the 
property of angular momentum, or spin. Simply put, some nuclei can be thought of 
as small spinning spheres. Since nuclei bear electric charges, their spinning 
produces a magnetic field analogous to the field produced when an electric current 
flows through a coil of wire. This results in a magnetic dipole moment oriented along 
the spinning axis. The nucleus of the hydrogen atom (1H) consists of a proton and 
possesses a magnetic moment. Because of its high natural abundance, sensitivity,
* Main sources used in this section are listed as references (14-17), which are also suggested as 
further reading material.
* In the remainder of this chapter 'NMR' will be referred to as 'MR', which is clinically more common.
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and presence in water and fat in the human body, it is the most important nucleus in 
medical MR.
When exposed to a static magnetic field, the randomly oriented magnetic dipoles 
line up with the magnetic field. To be more precise, the magnetic moment does not 
align exactly with the axis of the external magnetic field but precesses around it (see 
figure 2.1) at a rate given by the Larmor relationship
V = ®/2tc = yB0/2n (2.1)
where v is the resonance frequency in Hz, ® is the angular frequency in radians per 
second, y is the gyromagnetic ratio, and B0 is the static magnetic field. y is a nuclear 
constant characteristic for each type of nucleus. For protons, y/2n = 42.58 MHz/T 
which means that at a field strength B0 of 1.5 T the Larmor frequency for proton 
spins is about 63.8 MHz. A  collection of identical nuclei will precess with the Larmor 
frequency but with random phases relative to each other so that on average the net 
(macroscopic) magnetisation vector remains along the axis o f the external magnetic
Figure 2.1. Schematic diagram of a hydrogen nucleus (proton) exposed to a magnetic field B0. The 
spin of the positively charged proton results in a magnetic moment ft , which precesses around the 
axis of the magnetic field.
For a proton spin in a static magnetic field there are two possible basic states with 
orientations parallel and anti-parallel to the applied field, pertaining to a low and high 
energy state respectively. In MR, resonance occurs when radiofrequency (RF) 
energy is applied at the Larmor frequency, flipping the magnetic moments from their 
parallel (lower energy) to their anti-parallel (higher energy) states or vice versa.
In an external magnetic field more protons are in the lower energy state and the net 
magnetisation vector lies along the direction of the applied magnetic field. However, 
the only way to detect this magnetisation is to get it out of equilibrium. This can be
field.
F.
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done by applying an specific RF field perpendicular to the main magnetic field. An 
RF pulse with a specific duration and amplitude will rotate the net magnetisation by 
an angle of 90° (often referred to as a 90 degree pulse, see figure 2.2). Following 
this pulse, the magnetisation will precess in the transverse plane at the Larmor 
frequency, and this precessing magnetisation can be picked up with an antenna 
(coil). The signal that is received is called the free induction decay (FID).
Figure 2.2. Schematic representation of the net magnetisation (indicated by the bold arrow) aligned 
to the external magnetic field B0 being tipped into the transverse plane. Transverse net magnetisation 
can be accomplished by application of a 90 degree RF pulse.
2.2.2 Relaxation
When an excitation pulse is switched off, the spins start returning to their 
equilibrium. However, in their excited state, the nuclei can return to the ground state 
only by dissipating their excess energy to their surroundings. This process is called 
longitudinal (T1) relaxation. T1 relaxation is promoted by a surrounding nuclear 
environment with magnetic fields fluctuating at a frequency close to the Larmor 
frequency. These fluctuations are caused by rotational or translational motion of 
molecules. As the average rate at which molecules reorient is related to their size, 
the molecular environment of the nuclei (e.g. the presence of large molecules like 
proteins) determines their T1 relaxation time.
In addition to the inherent T1 of a tissue, MR contrast agents may be applied to 
modify this relaxation time. Gadolinium chelates are often used for this purpose. 
Gadolinium has a large magnetic moment because of its unpaired electrons, 
providing a strong fluctuating magnetic field at the Larmor frequency for protons in a 
magnetic field of ~1.5 T. As a result, the T1 will drop when protons get near the 
contrast agent.
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While the longitudinal magnetisation recovers to its equilibrium value, the transverse 
net magnetisation decays to zero. Nuclear magnetic moments contributing to the 
transverse net magnetisation get out of phase because of their mutual interaction, a 
process called T2 relaxation. All protons are affected by the magnetic fields of their 
neighbours, making them precess at slightly different Larmor frequencies. As a 
result, the magnetisation in the transverse plane begins to dephase, usually at a 
rate much faster than the longitudinal magnetisation recovers. The T2 of protons in 
water is primarily related to the intrinsic field caused by adjacent protons with low 
reorientation rates. For example, water molecules that are bound to biological 
macromolecules have efficient T2 relaxation and thus a shorter T2 relaxation time 
than 'free' water.
Figure 2.3. MR images of the author's head. Sagittal localizer image (left) indicating the position of 
the transversal slices (dashed line). Transversal T1 weighted image (centre) and T2 weighted image 
(right) of the brain.
The observed decay of the transverse magnetisation is usually faster than T2, due 
to imperfections in the main static magnetic field (field inhomogeneities). This also 
causes neighbouring protons to precess at different frequencies. The total rate of 
signal loss, due to a non-uniform magnetic field as well as T2 relaxation is 
characterised by T2*. Besides having an effect on T1, MR contrast agents like 
Gadolinium chelates also alter the apparent relaxation time T2*.
Differences in relaxation times provide contrast between different tissues in MR 
images. In figure 2.3 images are displayed showing differences in T1 (T1 weighted 
image) and differences in T2 (T2 weighted image) within the brain. Subtle 
differences in chemical, physical and biological properties of tissue may affect 
relaxation times. Tissue composition, structure, and surroundings, as well as 
inhomogeneities of the local magnetic fields within the tissue contribute to image 
contrast and may produce clinically useful differentiation between tissues.
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2.2.3 Principle of imaging
The MR image represents the MR characteristics of tissue at a predefined position 
in the human body. To create an image of a specific slice within the body and also 
to localise individual voxels (volume elements) within the slice, all voxels have to 
experience a unique magnetic field. In conventional MR imaging three different 
functions are used for this purpose: slice selective excitation, frequency encoding, 
and phase encoding. These can be accomplished by applying temporary gradients 
in the magnetic field.
In slice selection, protons in the imaging slice are selectively excited by means of a 
combination of a frequency selective RF pulse and a magnetic field gradient 
perpendicular to the imaging plane. The bandwidth of the RF pulse and the 
amplitude of the slice selection gradient determine the slice thickness. Spatial 
encoding within this slice can be done by frequency encoding and phase encoding. 
When a gradient is switched on, spins at different locations will experience different 
magnetic fields, and will precess with different Larmor frequencies. This procedure 
is called frequency encoding and causes the resonance frequency to be 
proportional to the position of the spin. Phase encoding uses a gradient to induce a 
specific phase angle to the transverse magnetisation vector. This phase angle 
depends on the location of the individual spin and the duration and amplitude of the 
gradient. By applying frequency and phase encoding both the frequency and phase 
of the spins contain spatial information, which is recorded in the MR signal. In the 
process of MR imaging gradients with different strengths and/or durations are 
applied consecutively, and the MR signals recorded are stored in a raw data matrix 
called k-space. This data contains all spatial information and can be processed 
using Fourier Transformation to produce an image.
2.2.4 Magnetic Resonance Spectroscopy
Whereas MR imaging mainly uses the signals from protons of water and fat to 
reconstruct an image, in MR spectroscopy the physical and chemical properties and 
concentrations of an extended set of metabolites are studied. Furthermore, MR 
spectroscopy can easily be applied to other nuclei than 1H; nuclei potentially useful 
for biomedical application include 13C, 19F, and 31P.
Chemical differences are manifest in the MR signal due to different shielding of the 
nucleus from the main magnetic field by the surrounding electrons. This results in an 
effective magnetic field
Beff = B0(1-g ) (2.2)
where o is the screening factor depending on the chemical environment of each 
nucleus. For example, in water, the electron cloud is drawn away from the hydrogen
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nuclei (protons), leaving them fairly unshielded. The electrons of hydrogen in a CH2 
group on a fatty acid chain are much closer to the hydrogen nucleus. These 
electrons shield the protons from the magnetic field and as a result their Larmor 
frequency is slightly different from those of water protons, by about 3 parts per 
million (ppm). This frequency shift is called 'chemical shift'. So, depending on its 
chemical environment, every nucleus resonates at a slightly different frequency. In 
MR spectroscopy signals are recorded at different frequencies, which are usually 
displayed in a spectrum. In figure 2.4 an example of an MR spectrum of the brain is 
shown. The horizontal axis of a spectrum represents the resonance frequency. The 
peak area reflects both the number of specific spins in a compound and the tissue 
content of that compound.
The property of chemical shift allows the MR spectroscopist to detect a wide variety 
of metabolites. Limiting factors for detection are the magnetic properties and the 
concentration of a compound. As the tissue levels of water and fat are much higher 
than those of other metabolites, MRS signals are much weaker than signals 
acquired using MRI. Therefore, in an MRS measurement multiple consecutive 
acquisitions are applied, and the resulting signals are averaged to obtain an 
acceptable level of signal with respect to noise (expressed as the signal-to-noise 
ratio, SNR).
NAA
ppm
Figure 2.4. Transversal MR image (left) of the brain. The white square indicates the position from 
which the spectrum was obtained. 1H MR spectrum (right) of the grey matter region indicated in the 
MR image. The main brain metabolites NAA, Glx, Cr, Cho, and Ino are labelled, see section 2.3.4 for 
details. (Sequence parameters: STEAM SVS, TR=2000 ms, TE=20 ms, 128 acquisitions.)
To obtain in vivo MR spectra from a particular type of tissue it is necessary to limit or 
localise the volume from which the signal is detected. Two techniques are 
commonly applied for this purpose (18). Single voxel spectroscopy (SVS) uses slice 
selective RF pulses in three dimensions to select the volume of interest. In MR 
spectroscopic imaging (MRSI) gradients are used for spatial encoding, analogous to
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the phase encoding technique used in MR imaging. Also a combination of phase 
encoding and slice selective pulses can be used. With MRSI, signals from multiple 
voxels in a grid can be obtained in one measurement. In this way, images of 
metabolite levels can be reconstructed, similar to MR images of anatomy.
2.3 Magnetic Resonance applications
2.3.1 Blood oxygen level dependent MRI
The blood oxygenation level dependent (BOLD) effect on MR signals was first 
demonstrated by Ogawa et al in a series of papers on a method to detect brain 
activation (19-21). In these papers the influence of the oxygenation level in venous 
blood on the signal intensity in MR images was shown. BoLD MRI is based on the 
magnetic properties of blood which are dependent on the oxygenation state of 
haemoglobin; deoxygenated haemoglobin is paramagnetic while oxyhaemoglobin is 
diamagnetic. Thus, deoxygenation results in an increased magnetic susceptibility 
difference between the vascular compartment and tissue (22). This susceptibility 
difference induces a local variation of the magnetic field strength around the vessels 
and capillaries, resulting in dephasing and signal loss in gradient echo (T2* 
weighted) images (21). In this way, deoxyhaemoglobin acts as an endogenous 
contrast agent.
Ogawa et al showed the feasibility of the BOLD method to detect activity in the 
human occipital cortex after a visual stimulus; a method that grew out to a widely 
used practical technique in current brain research (functional MRI, fMRI (23-25)). 
Soon also tumours were assessed using this technique, first in laboratory animals 
(e.g. 26-28) and subsequently in humans (e.g. 29-31), mainly to assess the effect of 
oxygenating agents. The physiological basis of the BOLD signal has been 
investigated extensively (32-34), however its exact contrast mechanism in MRI 
remains complicated. The BOLD signal proved to be sensitive not only to 
oxygenation, but also to changes in vascular volume and flow (28,35,36). In this 
respect, also the acronym FLOOD (Flow and Oxygenation Dependent) was 
introduced (27).
BOLD measurements have been used to assess the effect of carbogen breathing in 
a variety of tumours in humans (29-31). In most tumours a significant signal 
enhancement was seen on T2* weighted images, which was interpreted as an 
improved oxygenation. This was supported by studies of Al-Hallaq et al, who 
showed a correlation between microelectrode measurements of changes in tumour 
oxygenation due to carbogen breathing and BOLD MRI (37).
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2.3.2 Dynamic contrast enhanced MRI
The primary goal for the introduction of contrast agents in Magnetic Resonance 
Imaging was the possible improvement in medical diagnosis by better tissue 
characterisation. Most o f the currently available contrast agents are paramagnetic 
and focus upon relaxation time and susceptibility changes. Their effect is caused by 
a metal ion which contains unpaired electrons (e.g. Gd3+ in Gd-DTPA has 7 
unpaired electrons). The resulting shortening in relaxation times is usually measured 
by T1 weighted MR imaging.
Gadolinium-DTPA (Gd-DTPA) is an exogenous contrast agent that remains 
intravascular in normal brain tissue due to the blood brain barrier, but diffuses into 
the extravascular extracellular space (EES) in all other tissues. It normally does not 
cross the cell membrane and remains extracellular. Information on vascular 
structure and function can be acquired by dynamically monitoring the exchange of 
Gd-DTPA between blood plasma and the EES. Dynamic contrast enhanced MRI 
(DCE-MRI) has been widely used for the assessment of human tumours. Its 
diagnostic value has been shown in for example breast tumours (38,39), cervix 
tumours (40), and prostate carcinoma (41,42), both in tumour detection, 
identification, and staging.
Figure 2.5. Transversal dynamic contrast enhanced MR image of a patient with a hypopharynx 
tumour, recorded one minute after Gd-DTPA contrast administration (left). Pixels from which the 
signal intensity versus times curves were obtained are labelled a (artery), t (tumour), and m (muscle). 
At the right, signal intensity changes in blood and the different tissues due to the contrast agent are 
plotted versus time.
The procedure for a DCE-MRI measurement is a combination of administration of 
the contrast agent and recording a series of fast MRI contrast enhanced images. 
For this purpose, Gd-DTPA is usually administered as an intravenous bolus 
injection. DCE-MRI data of a series of consecutive images can be visualised in 
signal intensity versus time curves, as shown in figure 2.5. As the signal intensity
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changes reflect the local concentration of Gd-DTPA, this data can be used to 
characterise the vascular properties of different tissues. Also, the effects of agents 
or procedures with potential vasomodulating capabilities, e.g. carbogen breathing, 
may be investigated in this way.
2.3.3 Physiological pharmacokinetic models
Dynamic contrast enhanced MRI data can be used to gain insight in the underlying 
physiology of the tumour by applying a physiological pharmacokinetic model to the 
data. Several models have been developed to express this data in terms of 
physiological parameters. The most widely used are the model proposed by Larsson 
et al in 1990 (43) and the model proposed by Tofts and Kermode in 1991 (44). 
Although the two models are in general the same there are a few differences, mainly 
in the (physiological) assumptions that are being made. An extensive comparison of 
the models was discussed by the two authors in a joint study (45).
Both physiological pharmacokinetic models are commonly used to fit the 
concentration Gd-DTPA versus time data*. For proper interpretation of the model 
results however, one has to be aware of the assumptions that are made in the 
formulation of the model. Three important assumptions are: 1. compartments 
contain a uniform distribution of Gd-DTPA, 2. Gd-DTPA in the EES has arrived 
directly from a nearby capillary, and 3. there is fast exchange of all mobile protons 
within a tissue. A more elaborate overview of the model assumptions has been 
discussed by Tofts (46).
In its simplest form, the model consists of two compartments, a vascular (blood 
plasma) and an extravascular (EES) compartment, as is shown in figure 2.6. A rate 
constant defines the exchange of contrast medium between these compartments. 
The change of the Gd-DTPA concentration in the EES is described by (43,44,47)
= Ktrans Cp(t) - kep Ct(t) (2.3)
dt
with Ct : tissue concentration of Gd-DTPA (mM); Cp : arterial plasma concentration 
of Gd-DTPA (mM); kep : rate constant (min-1) between extravascular extracellular 
space and blood plasma; Ktrans : volume transfer constant (min-1), Ktrans = kepve and 
ve = volume of EES per unit volume of tissue (47). By setting the concentration of 
Gd-DTPA at the time of bolus injection to 0, the general solution of equation 2.3 is 
(43,44,47)
* Before DCE-MRI data is entered into the model, the measured signal intensity changes have to be 
converted into concentration of Gd-DTPA. Several mathematical methods can be used for this 
purpose, but description of these is beyond the scope of this chapter.
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Ct(t) = Ktrans- j  Cp(x)-e-kep(t-T)-dx (2.4)
The function Cp(t) is called the arterial input function (AIF). According to the model, 
this AIF should be measured in feeding arterial vessels at the capillary level. 
However, this is generally not possible and the concentration changes of Gd-DTPA 
in blood are usually measured in a larger artery. An example of the bolus passage 
of Gd-DTPA in an artery is shown in figure 2.5.
In the Larsson model the Gd-DTPA uptake rate is governed by several physiological 
parameters (43,47)
k ep _
E • F -  PS
with the extraction fraction E = 1 -  e (2.5)
with P: vascular permeability (cm m in -1); S: vascular surface area (cm2); F: tumour 
blood flow (m lm in -1) (47). For the sake of simplicity both haematocrit and tissue 
density are ignored here. The Gd-DTPA uptake rate can be displayed as a map by 
applying the physiological model to DCE-MRI data on a pixel-by-pixel basis. In this 
way spatial information can be obtained to identify and characterise tumour tissue 
and to map physiological changes in a tumour.
Figure 2.6. Physiological pharmacokinetic model containing two compartments: blood plasma 
(vascular compartment) and extravascular extracellular space (extravascular compartment), with Gd- 
DTPA concentrations of Cp(t) and Ct(t) respectively. The rate constant kep describes the exchange of 
Gd-DTPA between the two compartments.
F
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2.3.4 31P and 1H Magnetic Resonance Spectroscopy
Among all biomedically relevant MR detectable nuclei, 1H offers the highest 
sensitivity for MR spectroscopy (MRS) because of its relatively high gyromagnetic 
ratio and natural abundance. In spite of this, the majority of pioneering studies in the
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field of in vivo MRS dealt with the measurement of phosphorus (31P) containing 
metabolites, mainly because this was technically less complicated (48-50). The
31
dominant signals in P MRS of human tissues originate from adenosine 
triphosphate (ATP), phosphocreatine (PCr), inorganic phosphate (Pi), phospho-
31diesters (PDE), and phosphomonoesters (PME). An example of a P MR spectrum 
is shown in figure 2.7. Both ATP and PCr have key functions in cellular energy 
metabolism; ATP as a direct energy source and PCr as an energy buffering 
compound to support ATP homeostasis. PME and PDE are believed to act as 
phospholipid precursors and catabolites respectively and may thus provide 
information on membrane metabolism (51).
31Relative metabolite concentrations obtained from in vivo P MRS data have been 
used to study a wide range of physiological and pathophysiological phenomena,
31including cerebral ischemia (52,53) and tumour physiology. P MRS has been 
applied to numerous human cancers, both for tumour identification and monitoring 
treatment response (54-59). In general, metabolic characteristics of tumours include 
a high level of PME and PDE, and a low level of PCr with respect to normal tissues 
(55).
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31Figure 2.7. P MR spectrum of the author's neck. The signal was obtained mainly from muscle 
tissue. The metabolites ATP, PCr, PDE, P¡, and PME are labelled. (Sequence parameters: 
unlocalised BIRP (2kHz), TR=1800 ms, 500 acquisitions.)
The study of tissue metabolites by 1H MRS is more complicated because of the 
need to suppress the intense water and fat signals and by the large number of 
metabolites that produce signals in a relatively narrow chemical shift range. 
However, continued technical developments tackling these problems have made 
possible the detection and quantification of a wide range of metabolites. Nowadays,
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1H MRS is in widespread use for the elucidation of pathophysiology starting from 
investigations of cell cultures, body fluids, isolated organs, whole animals, up to the 
study of human patients.
A major application of 1H MRS is the study of brain tumours, mainly because the 
brain is relatively easy to assess by MR and difficult to investigate by invasive 
methods. Clinical usefulness of 1H MR spectroscopy includes diagnosis, design of 
the most favourable treatment regimens for each patient, and posttreatment 
monitoring (60,61). MRS may provide additional information in cases in which the 
differential diagnosis of tumours by MRI is difficult (62). Metabolic information 
obtained by MR spectroscopy has proven to be promising in the accurate diagnosis 
of human brain tumours (63-65). Furthermore, MRS showed to be an important 
guide for clinical decision making (66).
A 1H MR spectrum provides a metabolic fingerprint of the tissue under analysis, as it 
contains many metabolites involved in a variety of cellular functions. For example, a 
common observation in 1H MR spectroscopy of brain tumours is a decreased level 
of NAA and an increased level of Cho (64,67). NAA is a major brain metabolite 
involved in cell signalling, regulation of interactions of brain cells, and the 
establishment and maintenance of the nervous system (68). The presence of NAA 
is used increasingly in clinical MRS studies as a neuronal marker. Elevated Cho 
levels are consistent with an increased choline turnover in relation to membrane 
biosynthesis by proliferating cells (62).
An example of a 1H MR spectrum of normal brain tissue is shown in figure 2.4. The 
main metabolites include N-acetylaspartate plus N-acetylaspartylglutamate (NAA), 
glutamine plus glutamate (Glx), creatine plus phosphocreatine (Cr), choline 
containing compounds (Cho), and myo-inositol (Ino). An elaborate overview of 
metabolites found in 1H MR spectra of normal and pathological tissues has been 
provided by several authors, e.g. (69-71). Also, different MRS techniques to obtain 
1H MR spectra, and the clinical use of 1H MRS has been reviewed extensively in the 
past few years (60,64,72,73).
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CHAPTER 3
3.1 INTRODUCTION
Almost all malignancies of the larynx are squamous cell carcinomas, located at the 
mucosal surface. The most applied treatment strategies include radiation therapy or 
total or partial laryngectomy (1). The choice of treatment depends on the initial stage 
of the tumour. Less advanced laryngeal tumours can be treated by radiotherapy 
whereas more advanced tumours are best treated by surgery. Recently, also 
Accelerated Radiotherapy with Carbogen and Nicotinamide (ARCON) is being 
applied on laryngeal tumours, with promising results (2).
An important factor in treatment planning of laryngeal carcinoma is the accuracy of 
pretherapeutic staging. Further characterisation of the tumour, for example the 
determination of tumour vascularity, may also assist in the diagnosis and choice of 
treatment (3). To assess the exact tumour extension and characterisation, clinical 
and endoscopic tumour evaluation have clear limitations. Therefore both Computed 
Tomography (CT) and Magnetic Resonance Imaging (MRI) are being used in the 
staging of head and neck tumours. Comparative studies of both imaging techniques 
show that in general MRI offers the highest sensitivity in staging squamous cell 
carcinomas of the larynx (4-6). Also, although estimations of perfusion of head and 
neck tumours by CT are feasible, this is more commonly studied by MRI (e.g. 7-9).
With conventional MRI, the differences in signal intensity between tumour, muscle, 
fat and normal cartilage enable delineation of the tumour. The diagnostic accuracy 
can be increased with the use of contrast agents, especially in the evaluation of 
malignant tumours (10-12). However, MRI offers techniques to study not only 
tumour anatomy but also various aspects of tumour physiology in more detail. This 
may be of importance in treatment selection and may have prognostic significance. 
In the next section two important techniques will be discussed: fast dynamic contrast 
enhanced imaging to study tumour vascularity and blood oxygen level dependent 
imaging to study tumour oxygenation.
3.2 Functional MR imaging
Functional MRI, defined as MR investigations of dynamic physiological processes, 
can be applied both to normal and abnormal tissues. A leading application of 
functional imaging is the study of the normal brain in response to stimuli, using 
imaging techniques that are sensitive to oxygenation. In tumours, several 
approaches can be used to monitor physiological processes dynamically. Dynamic 
contrast enhanced MRI (DCE-MRI) and blood oxygen level dependent (BOLD) MRI 
are often applied nowadays, although also other MR techniques, e.g. blood pool 
contrast enhanced imaging or diffusion weighted imaging can be used. DCE-MRI 
can be applied to assess changes in vascularity, including vascular permeability,
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blood flow and blood volume. BOLD MRI can be used to assess changes in blood 
oxygenation status. In tumours, information about blood supply, vascular 
architecture and oxygenation status may be important factors determining the 
choice and outcome of therapy and may be helpful in selecting patients for various 
treatment strategies.
3.2.1 Vascularity
Tumours often feature a more chaotic vascular architecture than normal tissue and 
a heterogeneous blood supply. Shunting of blood flow within a tumour has been 
recognised together with variations in vascular permeability (7,13). Information on 
tumour vascularity may aid not only to the characterisation of tumours, but also to 
treatment planning. Tumour blood flow for example is of fundamental importance to 
the efficacy of chemotherapy (drug delivery) and radiotherapy (oxygen supply). 
Also, assessment of functional changes of tumour vasculature may be used to 
monitor treatment response.
Various aspects of vascularity, in particular vascular permeability and vascular 
surface area, can be assessed by DCE-MRI (14,15). Using this technique a contrast 
agent is administered and its uptake in tumour or normal tissue is monitored by fast 
imaging (temporal resolution ~seconds). Fast MR imaging techniques have not 
been applied frequently to laryngeal tumours yet. Most dynamic imaging studies so 
far employed a temporal resolution of 30 seconds or more. Using this technique 
images can be obtained with a high level of anatomical information, however the 
first pass effects of the contrast medium cannot be monitored. A higher temporal 
resolution can only be achieved at the expense of the spatial resolution. So, 
depending on the kind of information required, the best DCE-MRI technique can be 
applied. DCE-MRI techniques have been widely employed for the assessment of 
various human tumours in both detection, identification, and staging (16-19). For 
head and neck tumours, DCE-MRI has proven to be superior to conventional 
contrast enhanced imaging in delineating the margins and extent of tumour (8).
As a contrast medium, Gadolinium chelates are commonly used, in particular 
megluminegadopentetate (Gd-DTPA). This exogenous contrast agent remains 
intravascular in normal brain tissue due to the blood brain barrier, but in all other 
tissues it diffuses into the extravascular extracellular space (EES). In tumour tissue, 
the exchange of Gd-DTPA between blood plasma and the EES and the rate 
constant of this process can be studied. This Gd-DTPA uptake rate provides 
information about for example vascular permeability and vascular surface area. 
Usually Gd-DTPA is administered as a bolus to study first pass effects and fast MRI 
is applied until the contrast medium in the EES is in equilibrium with plasma.
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In head and neck tumours, investigation of tumour vascularity by DCE-MRI has 
been used to improve the detection of tumours, to determine the tumour extension, 
and to make differential diagnosis. Time curves obtained from dynamic MRI were 
shown to indicate differentiated grades and cell proliferating activity in thyroid 
tumours (20). DCE-MRI has also proven to be useful in the evaluation of therapy of 
head and neck cancers (21). Most malignant lesions of the head and neck show 
early enhancement and early wash-out of contrast media on DCE-MRI (9). This 
information may aid in predicting the response of tumours to chemotherapeutic 
treatment. Also, DCE-MRI studies have shown to be useful in predicting the 
response to accelerated radiotherapy for head and neck cancer (7).
3.2.2 Oxygenation
Tumour oxygenation is an important factor in the response of tumours to therapy, 
especially radiotherapy. Radiosensitivity is directly correlated to the oxygen 
concentration in the tumour; well-oxygenated cells are more radiosensitive than 
hypoxic cells (22). Increasing tumour oxygen levels may therefore improve the 
efficacy of radiotherapy. For laryngeal tumours, carbogen breathing and 
nicotinamide administration resulted in a significantly improved tumour response to 
accelerated radiotherapy (ARCON), most likely mediated by improved tumour 
oxygenation levels (2,23,24). Thus, information on the tumour oxygenation status is 
particularly valuable in predicting the outcome of radiotherapy and the effect of 
oxygenating agents.
Changes in tumour blood oxygenation, e.g. due to an oxygenation protocol can be 
assessed by BOLD MRI (25). This technique makes use of the different magnetic 
properties of oxyhaemoglobin and deoxyhaemoglobin. Unlike oxyhaemoglobin, 
deoxyhaemoglobin is paramagnetic and shortens the MRI time constant for the 
transverse magnetisation decay (T2*), resulting in an attenuation of MRI signals 
from tissue adjacent to (venous) blood vessels. Thus, deoxyhaemoglobin acts as an 
endogenous contrast agent, which can be monitored by gradient-echo MR imaging. 
Although the value of T2* was shown to relate directly to the concentration of 
deoxyhaemoglobin in normal brain tissue of laboratory animals (26), in tumours this 
value may be mainly governed by the magnetic field distortions caused by tissue 
inhomogeneity. Especially in laryngeal tumours this may be an important factor, 
because the border between tissue and air tends to distort the magnetic field to a 
large extent. However, monitoring changes in the value of T2* due to an 
oxygenating agent can be used to assess changes in local vascular oxygenation 
status.
So far, little information is available on BOLD MRI in patients with laryngeal cancer. 
Using oxygen electrodes, measurement of pretreatment oxygenation levels showed 
to be predictive of radiation response in patients with advanced squamous cell
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carcinomas of the head and neck (27). Oxygenating agents will increase the blood 
oxygen level, which could result in a decrease of the deoxyhaemoglobin 
concentration and an increase of the value of T2*. Therefore, the oxygenating 
effects on tumour tissue can be monitored noninvasively by measuring the change 
in the value of T2*. BOLD MRI of tumours may thus assist in the prediction of 
radiotherapy outcome and be used to investigate the effect of oxygenating agents 
on radiosensitivity.
3.3 MRI Methods
All data that is shown in this chapter has been recorded on a 1.5 T Siemens Vision 
whole body system (Siemens Medical Systems, Erlangen, Germany), using a CP- 
neck-array receive coil. For all studies from which this data has been obtained 
patients have given informed consent and approval has been obtained from the 
local ethics committee.
3.3.1 Dynamic contrast enhanced MRI 
MRI PROTOCOL
The procedure for a DCE-MRI measurement is a combination of administration of a 
contrast agent and recording fast MRI contrast enhanced images. As a contrast 
agent, Gadolinium-DTPA is most commonly used. Intravenous injection of Gd-DTPA 
can be applied either by hand or by an automatic injection system. An automatic 
injection system has the clear advantage that the contrast agent can be 
administered in a more reproducible way, which may be important in comparing the 
signal enhancement curves of two measurements of the same patient, for example 
before and after therapy. Gd-DTPA is usually administered in a dose of 15 ml (0.5 
M) of Gd-DTPA solution. This volume has to be administered as a bolus (e.g. 2.5 
ml/sec.) to be able to study first pass effects of the contrast medium in the tumour.
Fast dynamic contrast enhanced MRI techniques can be classified into two 
methods: T1 weighted and T2* weighted sequences. For dynamic contrast studies 
of the head and neck region, T2* weighted sequences are difficult to implement 
because of magnetic field inhomogeneity effects. Furthermore, T2* weighted 
imaging requires the Gd-DTPA contrast medium to remain intravascular for reliable 
assessment of the time-intensity curves (9); a prerequisite that is not met by 
laryngeal carcinomas. Under these conditions, T1 weighted imaging methods such 
as fast spin-echo and gradient-echo techniques are usually applied (8,28-30). To 
study the dynamics of the contrast medium in the tumour in detail, imaging 
sequences have to be fast. For the accurate measurement of tracer kinetic
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parameters the temporal sampling requirement is about 4 seconds, and if also time- 
intensity curves of large blood vessels have to be measured, the sampling rate 
should be even higher (31). DCE-MRI data acquired this way is shown in figure 3.1 
for a patient with a laryngeal tumour. The sequence parameters (2D FLASH, TR=50 
ms, TE=4.4 ms, a=60°, slice thickness 7 mm, 7 slices, matrix 2562, FoV 210x280 
mm) enabled reconstruction of an image every 2 seconds. The 6 images displayed 
in figure 3.1 are a subset of a data set of 44 consecutive images. The bolus 
passage of the contrast medium in the carotid and vertebral arteries can be 
recognised, as well as the dynamic contrast enhancement in the tumour.
Figure 3.1. Six transversal dynamic contrast enhancement images of a patient with a laryngeal 
tumour (T3) obtained from a data set of 44 images. The images were acquired as described in 
section 3.3.1 with a temporal resolution of 2 seconds. Images a-f were recorded at t=4, t=14, t=16, 
t=24, t=60, t=75 seconds respectively. Dynamic contrast enhancement in both normal tissue, tumour 
tissue and large blood vessels can be recognised.
Especially when a mobile organ like the larynx is being imaged, artifacts may be 
introduced in the dynamic contrast enhancement images. Patients with laryngeal 
tumours may have trouble breathing, which may introduce motion artifacts. Also, the 
laryngeal region is extremely sensitive to artifacts caused by swallowing. These 
artifacts are very difficult to correct for after the data has been recorded. So, to 
reduce motion artifacts on the images, the total measurement time of the set of 
dynamic contrast enhancement images should be kept short. The first pass effects 
and the washout of the contrast medium however, have to be sampled for an 
accurate measurement of dynamic contrast enhancement parameters. In practice, 
with a short bolus and a sampling rate of 2 seconds, a total measurement time of 90 
seconds suffices.
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Figure 3.2. Gd-DTPA uptake curve (dots) of 1 pixel in the tumour region and the fit of this curve (solid 
line) according to the physiological model by Larsson et al (32). The arterial input function (triangles, 
connected with a line) is also shown. The data was obtained from the same patient as in figure 3.1.
Data analysis
For clinical purposes, it may be sufficient to perform a parametric analysis of the 
DCE-MRI data, resulting in values of parameters such as maximum contrast 
enhancement and rate of enhancement. This approach may yield reliable data of 
clinical significance (e.g. 33). However, to minimise variations among patients and 
different measurements caused by variable systemic blood supply it is necessary to 
apply some kind of normalisation. As a reference the concentration-time curves of 
the contrast agent in the feeding vessels (arterial input function, AIF) can be used. 
The advantage of imaging laryngeal tumours compared to e.g. brain tumours or 
breast tumours is that multiple arteries are present in a transversal imaging slice 
through the tumour (vertebral and carotid arteries). Thus, the signal enhancement 
versus time curves in the tumour and in the arteries can be acquired simultaneously, 
without any additional measurements. The necessity to record the AIF for 
quantitative analysis o f DCE-MRI data was recently shown by Port et al (34) and 
Rijpkema et al (30) for various tumours, including laryngeal carcinomas. The Gd- 
DTPA uptake curve of a laryngeal tumour and the coregistered AIF are plotted in 
figure 3.2, showing clearly the bolus passage of the contrast medium and the (rate 
of) Gd-DTPA uptake in the tumour. To gain insight in the underlying physiology of 
the tumour various physiological pharmacokinetic models have been proposed to 
describe the dynamic MR contrast enhancement. Using these models DCE-MRI 
data may be described in physiological terms such as vascular permeability and 
surface area, extracellular volume and tumour blood flow.
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Physiological pharmacokinetic models
The most commonly used physiological models in DCE-MRI are those described by 
Tofts and Kermode (35) and Larsson et al (32). The measured concentration-time 
curves of the contrast medium in the tumour and the AIF serve as input for these 
models. The output consists of quantified physiological parameters like the rate 
constant of contrast medium uptake, which is directly related to, for instance, the 
vascular permeability and surface area.
In its simplest form a physiological pharmacokinetic model describing dynamic 
contrast medium uptake contains two compartments: blood plasma and EES. A rate 
constant defines the exchange of contrast medium between these compartments. 
This rate constant kep (36) is one of the three principle parameters in the analysis of 
T1 weighted contrast enhancement data. The two other parameters are the volume 
transfer constant between blood plasma and EES (Ktrans) and the volume of EES per 
unit volume of tissue (ve). These three physiological parameters are related 
according to kep = Ktrans / ve (36). When a physiological model is applied to DCE-MRI
Figure 3.3. (a) T1 weighted dynamic contrast enhancement image of the same patient as in figure 
3.1, recorded 75 seconds after Gd-DTPA contrast medium administration. The DCE-MRI data was 
analysed using the physiological model by Larsson et al (32). The results are shown in (b) map of the 
Gd-DTPA uptake rate (kep) and (c) map of the volume transfer constant (Ktrans) of the same patient.
patient stage kep (min-1)
1 IV 2.3 ± 0.7
2 III 1.3 ± 0.6
3 II 3.0 ± 1.3
4 III 2.8 ± 0.9
5 IV 1.9 ± 1.7
6 III 2.4 ± 2.5
7 III 2.3 ± 1.0
8 IV 2.9 ± 1.5
Table 3.1. The contrast medium uptake rate kep (min-1) in laryngeal tumours of 8 patients (± SD). The 
T classification of the tumour according to the TNM classification system is also indicated. The 
contrast medium uptake rate may provide information on e.g. vascular permeability and surface area.
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data on a pixel-by-pixel basis, maps can be reconstructed in which these 
parameters are displayed. In figure 3.3 a contrast enhancement image is displayed, 
together with maps of kep and Ktrans, for the same patient as in figure 3.1. The 
tumour can readily be distinguished from the surrounding tissue in all three images. 
However, spatial inhomogeneity within the tumour is more easily recognised in the 
parameter maps (figure 3.3b and c).
Figure 3.4. Six transversal T2* weighted images from a data set of 16 images recorded using a 
multiple gradient-echo sequence. The data was obtained from the same patient as in figure 3.1. 
Images a-f were recorded with an echo time of 6, 9, 15, 21, 27, and 36 ms respectively. The signal 
decay at increasing echo times was used to calculate the value of T2* (ms).
The characterisation of tumours by quantification of physiological parameters 
enables the direct comparison of tumour characteristics to those of other tumours. In 
table 3.1 the values of the Gd-DTPA uptake rate in laryngeal tumours is shown for 8 
patients. The T classification of the tumour according to the TNM classification 
system (37), describing the extent of the tumour, is also shown. Because the 
amount of quantified physiological DCE-MRI data on laryngeal tumours is still 
limited no correlation with tumour TNM classification could be found yet. This 
correlation is complicated further since histological data obtained by biopsy may not 
be representative of the whole tumour, especially when a tumour is heterogeneous, 
whereas the physiological parameters obtained by DCE-MRI so far are an average 
of the whole tumour.
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3.3.2 Blood oxygen level dependent MRI
MRI techniques to study tumour vascular oxygenation usually employ the BOLD 
effect. Using gradient-echo MRI changes in the value of the relaxation time T2* can 
be determined, which correlate to changes in the deoxyhaemoglobin concentration. 
Although changes in T2* are sensitive to changes in both blood volume, 
haematocrit, and oxygenation (38), the decrease in T2* during hyperoxygenation 
was shown to be strongly correlated with increased tumour pO2 levels, as measured 
using oxygen electrodes (39). Conventional T2* weighted MR imaging cannot 
distinguish accurately changes in blood oxygenation from changes in blood flow, 
because of inflow effects (40). To overcome this disadvantage a multiple gradient­
echo MRI technique can be applied, which can quantify T2* independently of effects 
of blood flow. In figure 3.4 data obtained with a multiple gradient-echo sequence is 
presented for a patient with a laryngeal tumour. In this figure 6 out of 16 images 
obtained with a 16-echo sequence are shown (sequence parameters: 16 echo 
FLASH, TR=65 ms, TE=6-51 ms, a=20°, 5 mm slice). Values of T2* (ms) can be 
calculated from the monoexponential signal decay at increasing echo times. This 
calculation can be performed on a pixel-by-pixel basis, enabling reconstruction of a 
map of T2*. In figure 3.5 a map is shown of the relaxation rate R2* (R2* = 1/T2*) 
obtained from the data set shown in figure 3.4. In this way, spatial information about 
tumour blood oxygenation changes can be visualised.
Figure 3.5. Map of the relaxation rate R2* (R2*=1/T2*) obtained from pixelwise analysis of the 
multiple gradient-echo data shown in figure 3.4. The R2* map is shown instead of the T2* map for 
display convenience.
In table 3.2 the values of T2* in laryngeal tumours are listed for 8 patients. The 
tumour values were obtained by averaging all pixels within a selected tumour region 
on the T2* maps. Although absolute T2* values are difficult to interpret directly in 
terms of tumour oxygen levels (see section 3.2.2), they may serve as 'baseline 
values' in the investigation of the effect of oxygenating agents on tumour blood
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oxygenation. An increase in the value of T2* caused by an improved blood 
oxygenation may indicate the radiotherapeutical usefulness of the oxygenating 
agent. For example, changes in T2* caused by breathing hyperoxic hypercapnic gas 
mixtures (e.g. 95-98% O2 plus 5-2% CO2) might predict whether the patient could 
benefit from radiotherapy treatment using these gas mixtures as a hyperoxygenation 
medium.
patient T2* (ms)
1 29.1 ± 1.8
2 26.9 ± 0.9
3 30.8 ± 2.0
4 32.5 ± 2.8
5 43.9 ± 2.5
6 37.2 ± 1.3
7 34.2 ± 2.7
8 24.5 ± 2.1
Table 3.2. The MRI time constant for the transverse magnetisation decay (T2*) (ms) in laryngeal 
tumours of 8 patients (± SD). These values are particularly important in the investigation of the 
effects of oxygenation agents on tumour blood oxygenation.
3.4 Laryngeal cancer: application of functional MRI approaches
An important treatment option for laryngeal cancer is radiotherapy. Although 
radiotherapy produces a high local control rate, in advanced carcinomas the 
radiation response is less good. Traditional prognostic factors, such as clinical 
staging, tumour size, and tumour extent, may not sufficiently predict results of 
radiotherapy (9). Blood flow and the presence of hypoxia in the tumour have long 
been considered important factors influencing the response to radiotherapy. 
Because functional MRI provides a way to assess tumour hypoxia by studying both 
functional changes in tumour vasculature and oxygenation status, the potential 
radiosensitising effect of oxygenating agents can be investigated.
For laryngeal tumours, increased tumour oxygenation levels achieved by carbogen 
breathing and nicotinamide administration resulted in a significantly improved 
tumour response to accelerated radiotherapy (ARCON), as was demonstrated by 
Kaanders and co-workers (2,23,24). Breathing a hyperoxic hypercapnic gas mixture 
like carbogen was hypothesised to increase the blood oxygen level which may 
reduce hypoxic regions in the tumour. The first results of their study show an 
actuarial local control rate at 3 years of 79% for T3 laryngeal carcinomas and 84% 
for T4 laryngeal carcinomas, higher than any previous report in the literature for this 
category of patients (24). Currently a randomised Phase III trial of this treatment is 
ongoing for laryngeal tumours.
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Breathing a hyperoxic hypercapnic gas mixture may have an effect on both blood 
flow and oxygenation (41,42). To study these effects in the clinic a combination of 
BOLD MRI and DCE-MRI techniques seems suitable. Recently, the effects of 
breathing a hyperoxic hypercapnic gas mixture (98% O2 + 2% CO2) were assessed 
by functional MRI techniques in patients with head and neck tumours (43). The main 
conclusion of this study was that breathing this gas mixture improved tumour blood 
oxygenation in these patients. No changes in tumour vascularity were found as 
assessed by the Gd-DTPA uptake rate. Furthermore, functional MRI proved to be a 
promising tool to investigate both tumour oxygenation and vascularity and might be 
developed into a predictive tool for testing treatments using hyperoxygenation for 
other types of tumours as well.
Figure 3.6. Functional MR images of a patient with a laryngeal tumour (T4). The images were 
recorded while the patient was breathing a hyperoxic hypercapnic gas mixture. (a) Sagittal image of 
the head and neck region showing the position of the transversal imaging slice used in both BOLD 
MRI and DCE-MRI. (b) Transversal dynamic contrast enhancement image of the same patient, 
recorded 1 minute after Gd-DTPA contrast medium administration. The image was acquired as 
described in section 3.3.1. (c) Volume transfer constant (Ktrans) map the of the same patient, 
providing information on tumour vascularity (see section 3.3.1 for details). (d) Relaxation rate (R2*) 
map of the same patient (see section 3.3.2 for details).
As an example to show the use of different functional MRI techniques to monitor the 
effects of hyperoxygenation in laryngeal tumours, a case is presented of a patient 
with a T4 laryngeal tumour. In figure 3.6 the results of the MR imaging study of this 
patient is shown. To investigate the effects of breathing a hyperoxic hypercapnic
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gas mixture on tumour oxygenation and vascularity, this patient was measured 
twice, once breathing air and once breathing a gas mixture consisting of 98% O2 
and 2% CO2. Tumour vascularity was assessed by DCE-MRI as described in 
section 3.3.1. Physiological parameter maps (e.g. Ktrans, figure 3.6b) were obtained 
from both the air breathing session and the session with breathing of the hyperoxic 
hypercapnic gas mixture. The values of the Gd-DTPA uptake rate kep are displayed 
in table 3.3. No significant differences could be detected, indicating that no extreme 
changes in vascularity occurred due to breathing the hyperoxic hypercapnic gas 
mixture.
Tumour oxygenation was assessed using BOLD MRI as described in section 3.3.2. 
The map of the relaxation rate R2* is shown in figure 3.6d. The values of T2* of the 
tumour obtained during air breathing and breathing the hyperoxic hypercapnic gas 
mixture proved to differ significantly (table 3.3); the value of T2* increased during 
hypercapnic hyperoxygenation. Although the T2* increase may seem small, it may 
reflect a much larger decrease in deoxyhaemoglobin concentration (26).
A powerful approach would be to combine the maps containing data on vascularity 
and oxygenation. A spatial relationship of the BOLD effect and the dynamic Gd- 
DTPA enhancement could provide useful physiological insight. However, in practice 
spatial correlation of the maps of the Gd-DTPA uptake rate and the (changes in) T2* 
is problematic. Even small shifts of the patient position between the measurements 
could dramatically affect a pixel-to-pixel correlation.
air carbogen significance
kep (min-1) 2.3 2.2 N.S.
T2* (ms) 29.1 31.4 p=0.02
Table 3.3. The contrast medium uptake rate kep (min-1) and the MRI time constant for the transverse 
magnetisation decay (T2*) (ms) of a patient with a laryngeal tumour. Data was obtained during air 
breathing and during breathing a hyperoxic hypercapnic gas mixture. The increased value of T2* 
during breathing this gas mixture indicates an improved tumour blood oxygenation. Statistical 
significance was shown using Student's t-test. N.S. = not significant.
In this patient Gd-DTPA uptake did not reveal any effect on tumour vascularity due 
to breathing of the hyperoxic hypercapnic gas mixture. However, as the blood 
oxygenation level increased in the tumour during breathing this gas mixture, this 
patient could benefit from radiation treatment using this hyperoxygenating agent. In 
fact, this patient was treated using the ARCON therapy and has not shown tumour 
recurrence after three years. Of course this case only is no proof of the benefit of 
breathing a hyperoxic hypercapnic gas mixture or the validity of the MRI methods as 
a predictive tool. A more robust study to prove this is currently ongoing.
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3.5 Conclusion
Functional MRI approaches of laryngeal cancer can be applied to study dynamic 
physiological processes and may aid in characterising physiological features of the 
tumour. Using dynamic contrast enhanced MRI various aspects of tumour 
vascularity can be assessed. Blood oxygen level dependent MRI enables 
investigation of blood oxygen levels in the tumour. Because for laryngeal 
carcinomas radiation treatment with hyperoxygenating agents has proven to be 
successful, studying the radiosensitising effects of these agents may provide 
valuable information. In this respect, functional MRI may be developed into a 
predictive tool for testing treatments using hyperoxygenation of laryngeal cancer.
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A bstract
A method is presented for the acquisition and analysis of dynamic contrast 
enhanced (DCE) MRI data, focussed on the characterisation of tumours in humans. 
Gadolinium contrast was administered by bolus injection and its effect was 
monitored in time by fast T1 weighted MRI. A simple algorithm was developed for 
automatic extraction of the arterial input function (AIF) from the DCE-MRI data. This 
AIF was used in the pixelwise pharmacokinetic determination of physiological 
vascular parameters in normal and tumour tissue. Maps were reconstructed to show 
the spatial distribution of parameter values. To test the reproducibility of the method
11 patients with different types of tumours were measured twice, and the rate of 
contrast agent uptake in the tumour was calculated. The results show that 
normalising the DCE-MRI data using individual coregistered AIFs, instead of one 
common AIF for all patients, substantially reduces the variation between successive 
measurements. It is concluded that the proposed method enables the reproducible 
assessment of contrast agent uptake rates.
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Introduction
Dynamic contrast enhanced MRI (DCE-MRI) using Gadolinium has been widely 
used for the assessment of human tumours. Its diagnostic value has been shown in 
for example breast tumours (1-3), cervix tumours (4) and prostate carcinoma (5-7), 
both in tumour detection, identification and staging. Also, tumour treatment 
response has been monitored by DCE-MRI (8-10) and comparison with histology 
showed a relationship of DCE-MRI data with angiogenic characteristics like 
microvessel density (6,7,11).
For clinical purposes, it may be sufficient to perform a parametric analysis of the 
DCE-MRI data, resulting in values of parameters such as maximum contrast 
enhancement and rate of enhancement. However, to minimise variations among 
patients and different measurements caused by variable systemic blood supply it is 
necessary to apply some kind of normalisation. To do so, signal enhancement of 
healthy tissue may serve as a reference (12,13), but a more direct reference would 
be to measure concentration-time curves of the contrast agent in the feeding 
vessels (arterial input function, AIF). Furthermore, parametric analysis alone does 
not provide insight in the underlying physiology of the tumour. For this purpose 
various physiological pharmacokinetic models have been proposed to describe 
dynamic MR contrast enhancement. Using these models DCE-MRI data may be 
described in physiological terms such as vascular permeability and surface area, 
extracellular volume and blood flow.
The most commonly used physiological models in DCE-MRI are the ones described 
by Tofts et al (14) and Larsson et al (15). For both models the AIF is required. To 
obtain this function from the experiments the measurement protocol has to have 
sufficient temporal resolution (16), especially when the contrast agent is applied as 
a bolus injection. Accurate measurement of the AIF allows quantification of 
physiological parameters like rate constant of contrast medium uptake, kep (17), 
which is directly related to, for instance, the vascular permeability and surface area.
Often, the AIF cannot be measured directly and a general concentration-time curve 
is assumed to be valid for humans, usually the one described by Weinmann et al 
(18). However, as large differences may exist in the AIFs of different patients, or 
even in the same patient at a different time, simultaneous measurement of DCE- 
MRI data of tumour tissue and the AIF is essential for correcting inter- and 
intrapatient differences (19,20). This normalisation of the DCE-MRI data is 
particularly important when one patient is measured more than once, for example to 
monitor the response to therapy.
In this study, we describe a method to measure both contrast medium uptake in 
human tumours and the AIF after bolus injection of Gadolinium. The rate constant of
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Gadolinium uptake is calculated and displayed in a quantitative kep map. The 
reproducibility of the method was tested in patients with brain tumours, prostate 
tumours and tumours in the head-neck region.
PATIENTS AND METHODS
MR imaging was performed on a 1.5 T Siemens Vision system. A total of 11 patients 
participated in this study. Data from 6 patients with a tumour in the head-neck region 
(1 larynx carcinoma, 3 hypopharynx carcinoma, 1 lymph node metastasis, 1 
melanoma of the nasal cavity), 3 patients with prostate carcinoma, and 2 patients 
with a brain tumour (2 oligodendroglioma) was recorded and processed using the 
current method. All patients gave informed consent to participate to this study. 
Approval for the study was obtained from the local ethics committee.
After conventional T1 and T2 weighted imaging, Gadolinium-DTPA (Gd-DTPA, 
Magnevist®, Schering, Berlin, Germany) was administered by intravenous bolus 
injection (15 ml, 0.5 M, 2.5 ml/sec.) using a Spectris™ MR injection system (Medrad, 
Inc.). Both Gd-DTPA tissue uptake and bolus passage in large blood vessels were 
monitored using a T1 weighted FLASH sequence with a temporal resolution of 2 
seconds. The sequence used was a 2D variant of the 3D TRICKS sequence 
described by Korosec et al (21). Briefly, k-space was divided in five sections which 
were sampled alternately, the central lines of k-space being acquired four times 
more frequent than the outer lines. Images were reconstructed using the sampled 
central lines of k-space; the outer lines of k-space were obtained by linear 
interpolation, as is shown in figure 4.1. Other sequence parameters were: TR=50 
ms, TE=4.4 ms, a=60°, slice thickness 7 mm, 7 slices, matrix 2562, FoV 210x280 
mm. DCE-MRI data was recorded for 90 seconds.
Before Gd-DTPA injection PD weighted images were recorded with the same 
sequence parameters as the DCE-MRI, except for the flip angle a=8° and the 
TR=200 ms. This image data was combined with the dynamic Gd-DTPA contrast 
enhancement image data to calculate concentration Gd-DTPA (a.u.) using the 
method described by Hittmair et al (22).
The concentration Gd-DTPA versus time curves were analysed using the Larsson
(15) model. An algorithm developed in our laboratory was used to obtain the AIF 
from the image data set. The selection of arterial blood vessel pixels by this 
algorithm was based on the relative concentration Gd-DTPA (high in arteries) and 
time to bolus passage (short in arteries). First, the average maximum Gd-DTPA 
concentration, [Gd-DTPA]max,average, was calculated for all pixels that showed 
contrast enhancement greater than zero. Then, a threshold was set at this [Gd- 
DTPA]max,average plus two times the standard deviation of [Gd-DTPA]max,avei-age.
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Although this factor of two was arbitrarily chosen, the algorithm proved to be quite 
insensitive to this threshold because the Gd-DTPA concentration in blood vessels is 
usually much higher than in tissue. In practice, virtually all pixels above this 
threshold were located in arteries and veins, as was confirmed by the radiologist. In 
the second step contributions from arteries and veins were separated from each 
other. To do so, a threshold was set at the time to the maximum Gd-DTPA 
concentration. This level was stepwise shortened with one inter-image interval until 
no pixels in a clearly visible vein were selected by the algorithm. The AIF was 
calculated as the average of the remaining selected pixels.
k-space lines
1 2  3 4
Figure 4.1. Diagram showing the acquisition order of the k-space sections (y-axis) and the 
interpolation used to reconstruct the MR images in time (x-axis). Central lines in k-space (section 
marked 'central') and outer lines (section marked 'outer') were sampled alternately. Reconstruction of 
an image (in this example image number 4) was done using the sampled central lines of k-space to 
which the outer lines were added by linear interpolation as indicated by the arrows.
For patients with tumours in the head-neck region the AIF found originated largely 
from pixels in the carotid artery and vertebral artery. These arteries were measured 
in the same transversal DCE-MRI slice as the tumour. In a similar way, for patients 
with prostate tumours, the AIF found originated from pixels in the external iliac 
artery. To obtain the AIF for brain tumours, one transversal DCE-MRI slice was 
positioned caudally to the slice showing the tumour in such way that the basilar 
artery and the internal carotid artery were visible. The AIF was then calculated as in 
the head and neck tumour patients.
Data was transferred to a SUN Ultra 10 workstation (UltraSPARC-IIi, 440 MHz, 1 Gb 
RAM) where the Larsson model was implemented in a Matlab routine. The function
Ct(t) = f-Ktrans- J Cp(x-AT) e-kep(t-T) dx = f-Ktrans-e-kep(t) * Cp(t-AT) (4.1)
0
was used to describe the transport of Gd-DTPA across the capillary membrane. Ct : 
tissue concentration of Gd-DTPA (mM); Cp : arterial plasma concentration of Gd-
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DTPA (mM); kep : rate constant (s-1) between extravascular extracellular space 
(EES) and blood plasma; Ktrans : volume transfer constant (s-1); ve : volume of EES 
per unit volume of tissue, kep=Ktrans/ve (17). AT (s) is the time delay of the tissue 
enhancement curve relative to the AIF (23). Factor f is a scaling factor and is 
dependent on the MR method used and the relaxation properties of the tissue. The * 
denotes a convolution operation. For Cp(t) the raw data of the AIF as described 
above was used, without fitting this data.
The fit results were reconstructed into maps of kep (s-1), Ktrans (a .u.s-1) and ve (a.u.) 
on a pixel-by-pixel basis. No smoothing or averaging was performed. The 
calculation time was less than 2 hours for most data sets.
To test the reproducibility of the method all patients were measured twice, with at 
least 24 hours between the sessions. To compare the results of the two 
measurements the average kep of the tumour was calculated. For this purpose, up to 
100 pixels were randomly selected from enhancing tumour regions on the T1 
weighted DCE-MRI image recorded 90 seconds after Gd-DTPA administration. The 
kep values of these pixels were averaged and the tumour was characterised by the 
mean kep and its standard deviation.
Results
On the T1 weighted MR image, which was obtained 90 seconds after Gd-DTPA 
administration, the presence of a head and neck tumour can readily be detected as 
illustrated in figure 4.2a for a patient with a hypopharynx tumour. The white line in 
figure 4.2b indicates the border of the tumour as determined by the radiologist. For 
further analysis of this tumour region by DCE-MR imaging the AIF was determined 
by the algorithm described in the previous section. 33 pixels were selected in the 
vertebral and carotid arteries as indicated in black in figure 4.2b. Pixels located in 
the arteries that were not selected by the algorithm either showed extreme artifacts 
or a bolus passage less than one inter-image interval (2 sec) earlier than in the 
veins. The AIF calculated from the selected pixels is shown in figure 4.2d. The solid 
line through the AIF data (squares) only connects the data points. The Gd-DTPA 
uptake data of 1 pixel in the tumour region is also shown in this figure (circles). The 
result of the fit according to equation 4.1, using for Cp(t) the AIF, is indicated by the 
solid line through the tumour data points. The value of kep derived from this fit was 
1.52 min-1. Values of kep derived for all pixels were reconstructed into a kep map 
(figure 4.2c).
In the kep map of the patient with a hypopharynx tumour (figure 4.2c) the tumour can 
be clearly distinguished from the surrounding tissue, suggesting its diagnostic value. 
The kep map also shows several lymph nodes (e.g. one located laterally to the
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tumour and indicated by the arrow in figure 4.2c), which suggests a potential 
importance of this method in detecting metastases. Furthermore, spatial 
inhomogeneity in Gd-DTPA uptake rates within the tumour can be seen, which can 
be visualised in quantitated kep histograms. This tool may be an important asset in 
the evaluation of treatment response and prediction of treatment outcome by 
distinguishing areas with high Gd-DTPA uptake rates from necrotic areas with low 
uptake rates. As an example, the kep histogram of all pixels of the tumour of patient 
1 is shown in figure 4.3.
d time (s)
Figure 4.2. (a) T1 weighted DCE image of a patient with a hypopharynx tumour recorded 90 seconds 
after Gd-DTPA administration. (b) The same image, with the AIF pixels as selected by the algorithm 
shown in black. The white line marks the ROI of the tumour. The central part of the tumour 
(consisting of air) was excluded from the analysis. (c) The kep map of the same patient. The arrow 
indicates a clearly visible lymph node, suggesting potential importance of mapping the Gd-DTPA 
uptake rate in detecting metastases. (d) Gd-DTPA uptake curve (circles) of 1 pixel of the tumour 
region and of the fit of this curve according to equation 4.1 (solid line). The AIF (squares, connected 
with a line) is also shown.
The reproducibility of the present method was tested in 11 patients with tumours in 
the brain, prostate and head and neck region. The results of this test are shown in 
figure 4.4. In ten of the eleven patients no significant difference in the mean value of 
kep was found between the two measurement sessions (Student's t-test, p>0.05); in 
one patient this difference was significant (p=0.02). The standard deviation of the
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mean kep for each patient reflects the fit error and the measurement error including 
motion artifacts. Also, inhomogeneity of the tumour will contribute to the value of this 
standard deviation. For this reason small changes in the average kep may remain 
undetected.
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Figure 4.3. Histogram of all pixels of the tumour region shown in figure 4.2, visualising the distribution 
of kep values. Spatial inhomogeneity in Gd-DTPA uptake rates within the tumour is clearly visible. 
Low values of kep may correspond to necrotic areas which often show slow contrast enhancement (if 
any), high values of kep usually indicate tumour areas containing many (permeable) vessels, which 
may coincide with active growing tumour tissue.
The necessity to normalise DCE-MRI data individually for further (pharmacokinetic) 
assessment followed from an analysis using a general concentration-time curve as 
AIF, instead of using coregistered AIFs for each examination. This general AIF was 
obtained by averaging 20 AIFs of patients with tumours in the head-neck region. 
Again, reproducibility of the method was tested. The results are shown in figure 4.5. 
Statistically significant differences between the two measurement sessions were 
found in 6 out of 11 patients (Student's t-test, p<0.05), showing a poor 
reproducibility using this general AIF method and the inaccuracy made when 
assuming no intra- and interindividual differences.
Furthermore, significant differences in the actual values of kep were found between 
the two data analysis methods, using a coregistered AIF (figure 4.4) and using a 
general AIF (figure 4.5). Assuming the first method will generate more accurate 
'true' values of kep, errors up to a factor 2 are being made in the second method.
Discussion
We demonstrated the application of a DCE-MRI method which allows reconstruction 
of quantitative spatial maps of the rate of Gd-DTPA contrast uptake in tissue (kep) 
after bolus injection of Gd-DTPA. Values of kep were normalised using a
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coregistered AIF enabling comparison of intra- and interpatient data. This method 
proved to yield very reproducible results.
A key factor in the present method is measuring the AIF after bolus injection of Gd- 
DTPA. Especially in large arteries flow and pulsation artifacts may be visible. 
Because of these artifacts manually selecting all pixels in an artery led to non- 
reproducible results. Pixels near the vascular wall often showed less extended 
artifacts than pixels in the centre of large arteries, possibly because of the 
decreased blood flow near the vascular wall. Implementation of a simple automated 
algorithm to select the AIF pixels (search for rapid and large contrast enhancement) 
increased reproducibility to a high level. The algorithm has two main advantages in 
comparison with manual selection of AIF pixels. Firstly, all arteries in the image are 
used to obtain the AIF. Also contributions from small arteries consisting of only a 
few pixels are included, leading to a more robust AIF. Secondly, extreme artifacts 
which may exist in arteries are automatically discarded, leading to more 
reproducible results. In all patients practically all pixels that were selected by the 
algorithm were located in arteries clearly visible on MRI, demonstrating the 
feasibility of the algorithm for this purpose. A similar method to select AIF pixels has 
been described by Rempp et al (24), who applied dynamic T2* weighted MR 
imaging of the normal brain after a bolus injection of Gd-DTPA. In their study 
however, a gamma variate function was used to extract the measured 
concentration-time curves. Threshold values of the parameters of this function were 
defined using an interactive computer program to select AIF pixels.
A difficulty in acquiring the AIF is the T2* shortening in regions of high Gd-DTPA 
concentration. Extreme T2* shortening may lead to signal decrease, especially at 
the top of the bolus passage. Although pixels showing extreme T2* effects are 
automatically discarded by the algorithm, the top value of the selected AIF may be 
attenuated to some extent. However, even a 50% decrease or increase of the top 
value of the AIF led to only 10% change in the value of kep, as was tested in three 
patients. The sequence used in the present study had already been optimised to 
reduce T2* effects. Avoiding these effects further may be done by either using a 
different type of sequence (e.g. 25) or to lower the dose of the bolus Gd-DTPA.
Another method to apply the contrast medium is by infusion. Knopp et al (26) and 
Hoffman et al (27) showed good DCE-MRI results using a 1-minute infusion of Gd- 
DTPA and incorporating the shape of the AIF by modelling its monoexponential 
decay. In this way, accurate estimation of the AIF may be facilitated (19), as artifacts 
will be less. However, first pass dynamics cannot be measured in this approach. 
Furthermore, as Henderson et al (16) discussed, a rapid bolus injection may reduce 
the error in estimations of Gd-DTPA uptake.
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Figure 4.4. Graph showing the results of the reproducibility test of the proposed method. Eleven 
patients were measured twice (session 1 and 2) and kep values were calculated for the tumour 
region. No statistically significant differences were found between the two measurement sessions in 
all but one patient (marked *, Student's t-test, p>0.05). Patient numbers: (1) larynx carcinoma, (2-4) 
hypopharynx carcinoma, (5) lymph node metastasis, (6) melanoma, (7-9) prostate carcinoma, (10­
11) brain tumour.
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Figure 4.5. Graph showing the results of the reproducibility test of the data analysis method using a 
generalised AIF. Eleven patients were measured twice (session 1 and 2) and kep values were 
calculated for the tumour region. In 6 out of 11 patients statistically significant differences were found 
between the sessions (marked *, Student's t-test, p<0.05), showing a poor reproducibility.
Larsson et al (25) and Fritz-Hansen et al (28) showed the feasibility of MRI 
measurement of the AIF compared to arterial blood sampling in healthy volunteers 
and the necessity to normalise DCE-MRI data using this AIF. Port et al (20) also 
demonstrated the need for monitoring arterial kinetics of Gd-DTPA individually when 
determining contrast medium exchange rates between blood and tumour in patients 
with mammary tumours. When the first pass of the contrast agent is not sampled, 
for example when DCE-MRI data is recorded with low temporal resolution, 
differences in AIFs may be less pronounced. In studies using laboratory animals
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(29-31) AIFs may be more similar and less interindividual differences may exist due 
to their more identical (genetic) background. Simpson et al (32) showed that 
substantial errors are introduced using a common AIF instead of individual AIFs in 
rats, but that these errors can be minimised with proper experimental strategies.
When analysing DCE-MRI data using the Tofts or Larsson model one has to be 
aware of the assumptions that are being made in these models (33). In this respect, 
physiological interpretation of the parameters in the model may not be trivial. The 
rate constant kep is not solely dependent on vascular permeability, but may be 
governed by other physiological parameters as well (34,35). In particular, as one 
MRI voxel generally contains both tissue and blood vessels, perfusion of these 
vessels may become an important contributing factor. Thus, without prior 
knowledge, a kep map can neither be interpreted simply as a permeability map nor 
as a perfusion map. Physiological specificity may be increased by including a 
plasma volume term (vpCp) into the data analysis (equation 4.1), but this will only 
make a valuable contribution to the analysis when this term can be determined with 
good precision (33). Su et al (29) proposed a method to separate contributions from 
blood vessels and extravascular components to the Gd-DTPA uptake rate in rats, 
assuming a generalised AIF. Recently, Li et al (36) showed a method to generate 
permeability maps corrected for contributions from vessels in brain tumour patients.
Pixelwise mapping of kep would allow one to perform a pixel-to-pixel analysis of data 
of the same patient at different sessions. In practice this is quite difficult, because an 
exact slice match is necessary for this purpose. Even a small shift can be 
problematic for performing a pixel-to-pixel analysis, especially in regions of interest 
with large heterogeneity. In this case, histograms of kep (see figure 4.3) may prove 
valuable to provide a way in the analysis of the distribution of the Gd-DTPA uptake 
rates in the tumour region.
Besides kep maps also Ktrans and ve maps were generated from the DCE-MRI data in 
this study. However, due to the scaling factor f (see equation 4.1) these parameters 
could not be expressed in absolute quantitated values. To do so, knowledge would 
be required not only about the T1 before Gd-DTPA injection, but also about the 
tissue relaxivity, which can generally only be approximated (33).
In conclusion, a method is described to measure reproducibly both Gd-DTPA uptake 
in human tumours and the AIF after bolus injection of Gd-DTPA, and to generate 
maps of physiological parameters from this DCE-MRI data.
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Abstract
For head and neck tumours breathing a hyperoxic hypercapnic gas mixture and 
administration of nicotinamide has been shown to result in a significantly improved 
tumour response to accelerated radiotherapy (ARCON, Accelerated Radiotherapy 
with CarbOgen and Nicotinamide). This may be caused by improved tumour 
oxygenation, possibly intermediated by vascular effects. In this study, both blood 
oxygenation and vascular effects of breathing a hyperoxic hypercapnic gas mixture 
(98% O2 + 2% CO2) were assessed by Magnetic Resonance Imaging (MRI) in 
patients with head and neck tumours. Tumour vascularity and oxygenation were 
investigated by dynamic Gadolinium-DTPA contrast enhanced MRI and Blood 
Oxygen Level Dependent (BOLD) MRI respectively. Eleven patients with primary 
head and neck tumours were each measured twice; with and without breathing the 
hyperoxic hypercapnic gas mixture. BOLD MR imaging revealed a significant 
increase of the MRI time constant of transverse magnetisation decay (T2*) in the 
tumour during hypercapnic hyperoxygenation, which correlates to a decrease of the 
deoxyhaemoglobin concentration. No changes in overall tumour vascularity were 
observed, as measured by the Gadolinium-DTPA contrast agent uptake rate in the 
tumour. In conclusion, breathing a hyperoxic hypercapnic gas mixture improves 
tumour blood oxygenation in patients with head and neck tumours, which may 
contribute to the success of the ARCON therapy.
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Introduction
Both tumour blood flow and oxygenation are important factors determining the 
outcome of cancer therapy. As well-oxygenated cells are more radiosensitive than 
hypoxic cells (1), increasing tumour oxygen levels may improve the efficacy of 
radiotherapy. Hypoxia may occur in cells that are located relatively far away from a 
blood vessel ('chronic' or 'diffusion limited' hypoxia (2)) or it may be induced by local 
fluctuations of blood flow ('acute' or 'perfusion limited' hypoxia (3,4)). Both 
mechanisms underlying hypoxia have to be dealt with to realise the best clinical 
outcome for radiotherapy.
Studies by Kaanders and co-workers (5,6) showed that treatment results in 
advanced head and neck tumours can be improved successfully by accelerated 
radiotherapy with carbogen and nicotinamide (ARCON). The mechanism of action of 
carbogen and nicotinamide is thought to be an increase in tumour oxygenation and 
thus a reduction of hypoxic regions in the tumour. The first results of their study 
show an actuarial local control rate of 80% at 3 years for carcinomas of the larynx, 
higher than any previous report in the literature for this category of patients (6). Also 
for patients with bladder carcinoma ARCON therapy resulted in a significant 
improvement of local control, progression free survival, and overall survival (7). For 
both tumour types randomised Phase III trials are ongoing.
Breathing a hyperoxic hypercapnic gas mixture like carbogen (95% O2 + 5% CO2) 
may have an effect on both tissue oxygenation and blood flow (8-10). The oxygen 
component in the gas mixture causes arterial haemoglobin to be fully oxygenated, 
and increases the blood oxygen tension (pO2) to a large extent (11-14). The effect 
of carbogen breathing on blood flow is more complex (9,15). Simplistically, CO2 is a 
vasodilator at a vascular level and may increase blood flow, whereas high 
concentrations of oxygen have a potential to decrease blood flow (16,17). Recently 
however, using intravital microscopy tumour vascular response to hyperoxygenation 
and hypercapnia was shown to be heterogeneous and dependent on vascular 
function and maturation (14).
Magnetic Resonance Imaging (MRI) provides non-invasive ways to study tumour 
physiology. Both functional changes in tumour vasculature and oxygenation status 
can be studied to assess treatments of tumour hypoxia. Furthermore, the high 
spatial resolution of MRI enables investigations of the heterogeneous vascular 
response throughout the tumour. MRI techniques to study tumour vascular 
oxygenation usually employ the Blood Oxygen Level Dependent (BOLD) effect (18). 
This effect is based on the different magnetic properties of deoxyhaemoglobin and 
oxyhaemoglobin. Unlike oxyhaemoglobin, deoxyhaemoglobin is paramagnetic and 
shortens the MR time constant for the transverse magnetisation decay (apparent 
spin-spin relaxation time, T2*), resulting in an attenuation of MRI signals from water
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in tissue adjacent to blood vessels. The BOLD effect in human tumours has been 
assessed by gradient-echo MRI (19). Using this technique changes in the value of 
T2* can be determined, which correlate directly to changes in the deoxyhaemoglobin 
concentration (20) and thus provide information on changes in local vascular 
oxygenation.
In tumours, newly formed blood vessels usually show structural and functional 
abnormalities with regard to their spatial distribution, morphology, dimensions and 
permeability (21). To study various aspects of tumour vascularity including blood 
flow, permeability, and vascular volume, dynamic Gadolinium-DTPA contrast 
enhanced MRI can be used (22). This technique has been widely employed for the 
assessment of human tumours both in detection, identification, and staging (e.g. 23­
25).
Both BOLD MRI and Gadolinium-DTPA contrast MRI have been used extensively to 
study the effects of oxygenating agents and blood flow enhancement on tumour 
hypoxia in laboratory animal models (e.g. 13,26-28). Tumour blood flow may 
respond heterogeneously when challenged with a hyperoxic hypercapnic gas 
mixture, which may be due to the association of blood vessels with smooth muscle 
cells (14). In this respect, also the 'steal' effect is well-recognised: blood flow may be 
increased locally at the expense of an adjacent location, depending on the tumour 
vascular bed (13,29). The effect of breathing a hyperoxic hypercapnic gas mixture 
on tumour oxygenation seems to be more clear, resulting in an improved 
oxygenation status in most experimental tumours. In mice, not only tumour pO2 was 
shown to increase during carbogen breathing, but also radiation response was 
enhanced under these conditions (30).
Although the clinical ARCON therapy leads to promising results in tumour treatment, 
the precise mechanism of action of breathing a hyperoxic hypercapnic gas mixture 
remains unclear. Animal studies suggest that an improved tumour oxygenation may 
contribute to the success of the ARCON therapy by reducing hypoxic regions in 
tumour. In humans, little information on the effects of breathing a hyperoxic 
hypercapnic gas mixture is currently available. MRI may be a suitable tool to 
investigate both changes in blood oxygenation and vascularity and may assist in the 
prediction of response to treatments using hyperoxygenation. In this study, BOLD 
MRI and Gadolinium-DTPA contrast enhanced MRI techniques were combined to 
assess the effects of breathing a hyperoxic hypercapnic gas mixture on the 
oxygenation and vascularity of head and neck tumours.
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Methods and materials
Eleven patients (10 males, 1 female) with squamous cell carcinomas of the larynx 
(n=6), hypopharynx (n=3) and oropharynx (n=2) were included in the study. The 
mean age was 56 years (45-67 years). All patients met the eligibility criteria of the 
ARCON clinical trial (31) and gave informed consent to participate to this study. 
Approval for the study was obtained from the local ethics committee.
MR imaging was performed on a 1.5 T Siemens Vision whole body system 
(Siemens Medical Systems, Erlangen, Germany) using a CP-neck-array coil. All 
patients were studied twice; once breathing air and once breathing a gas mixture of 
98% O2 and 2% CO2. This hyperoxic hypercapnic gas mixture is also used in the 
ARCON clinical trial for head and neck tumours. The time between the two sessions 
was at least 24 hours. Gadolinium-DTPA (Gd-DTPA, Magnevist®, Schering, Berlin, 
Germany) was administered by intravenous bolus injection (15 ml, 0.5 M, 2.5 ml/s) 
using a Spectris™ MR injection system (Medrad, Inc.). This MRI contrast agent is 
routinely used for vascular investigations.
In the first session conventional T1, T2, and proton density weighted images were 
recorded and after administration of the contrast medium Gd-DTPA tissue uptake 
was monitored for 90 seconds (FLASH, TR=50 ms, TE=4.4 ms, a=60°, 7 mm slice,
2 seconds temporal resolution). In the second session 28 multiple gradient-echo 
images (16 echo FLASH, TR=65 ms, TE=6-51 ms, a=20°, 5 mm slice (32)) were 
recorded for 14 minutes whilst breathing air. Subsequently breathing of the 
hyperoxic hypercapnic gas mixture was started and 12 gradient-echo images were 
recorded for another 6 minutes, followed by Gd-DTPA contrast enhanced imaging 
as in the first session.
T2* values (ms) were calculated from the gradient-echo imaging data (32). The 
value of T2* in the tumour was obtained by averaging all pixels within the selected 
tumour region. Although the mask for supplying the hyperoxic hypercapnic gas 
mixture was positioned carefully, air leaks might occur in the experimental setup. 
Therefore, patients were checked for inhaling the gas mixture properly by measuring 
the T2* in venous blood. If no statistically significant increase (Student's t-test) in the 
value of T2* in the jugular vein was observed during hypercapnic hyperoxygenation 
the measurement was considered a technical failure.
The dynamic Gd-DTPA contrast image data was analysed as described by 
Rijpkema et al (33). The rate of contrast medium uptake (kep (s-1) (34)) was 
calculated using the physiological pharmacokinetic model of Larsson et al (35). The 
concentration-time characteristics of the contrast medium in arterial blood were 
used to normalise the data. Maps of kep were reconstructed from the value of kep for 
each pixel. The Gd-DTPA uptake rate of the tumour during air breathing and
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breathing the hyperoxic hypercapnic gas mixture was calculated by averaging the 
values of kep in Gd-DTPA enhancing regions of the tumour.
To uncover spatial heterogeneity pixels in the tumour region were selected from the 
T2* and kep data and displayed as histograms of T2* and Gd-DTPA uptake rate. In 
this way the effects of hypercapnic hyperoxygenation on the relative distribution of 
these parameters could be assessed in more detail.
Figure 5.1. (a) Transversal MR image of a patient with a hypopharynx tumour, recorded before Gd- 
DTPA contrast administration. The arrow indicates the tumour. The image was obtained at the end of 
a 10-minutes period of breathing the hyperoxic hypercapnic gas mixture. (b) Dynamic contrast 
enhanced MR image of the same patient, recorded one minute after Gd-DTPA contrast 
administration. MR signal intensity in the tumour region is clearly enhanced. (c) Map of the Gd-DTPA 
uptake rate kep of the same patient, providing information on tumour vascularity. The kep map was 
calculated from the contrast enhanced MRI data set as shown in figures 5.1a and 5.1b. (d) The R2* 
map at the same slice position of the same patient during breathing the hyperoxic hypercapnic gas 
mixture, showing clear heterogeneity within the tumour.
RESULTS
Eleven patients were measured successfully using the current MRI protocol. From 
the 17 initially selected patients, 6 dropped out of the study or were eliminated from 
the study for technical reasons. In two patients severe claustrophobia necessitated
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the early abort of the MRI measurement, in two patients no significant increase in 
the value of T2* in the jugular vein was observed during breathing the hyperoxic 
hypercapnic gas mixture and the measurement was considered a technical failure, 
in one patient measurements were discontinued because of artifacts on the MR 
images caused by a metal implant in the mandible, and one patient was unable to 
breathe the hyperoxic hypercapnic gas mixture and dropped out of the ARCON 
study. Four patients were slightly claustrophobic or unusually restless during the MR 
measurement and the protocol was shortened by recording fewer gradient-echo 
images during air breathing, to a minimum of 15 images (7.5 minutes).
patient kep (tumour, air) 
(min-1)
Akep
(%)
1 2.3 ± 0.7 -7.7 ± 4.2
2 3.0 ± 1.3 6.0 ± 6.1
3 2.8 ± 0.9 12.8 ± 11.0
4 1.3 ± 0.6 4.5 ± 8.3
5 1.3 ± 0.7 -14.3 ± 8.2
6 2.6 ± 0.9 -11.4 ± 6.6
7 1.4 ± 0.5 8.3 ± 6.6
8 1.8 ± 0.4 6.7 ± 4.5
9 2.3 ± 1.0 5.1 ± 7.1
10 2.9 ± 1.1 10.0 ± 7.2
11 1.4 ± 0.4 4.2 ± 3.0
Table 5.1. Values of the Gd-DTPA uptake rate kep of the tumour during air breathing and the change 
due to breathing the hyperoxic hypercapnic gas mixture. Values are presented as mean ± standard 
deviation. Akgp = kep(hyperoxic hypercapnic gas mixture) - kep(air), expressed as % with respect to 
kep(air). In none of the patients the hypercapnic hyperoxia induced change in Gd-DTPA uptake rate 
was statistically significant (Student's t-test, p>0.05).
MR signal intensity in the tumour region clearly enhanced after Gd-DTPA 
administration, as is shown in figures 5.1a (pre-contrast) and 5.1b (post-contrast) for 
a patient with a hypopharynx tumour. This contrast enhanced MRI data was used to 
reconstruct maps of the rate of contrast agent uptake, kep, as shown in figure 5.1c 
for the same patient. The average values of the Gd-DTPA uptake rate of the tumour 
during air breathing and breathing the hyperoxic hypercapnic gas mixture were 
calculated from the corresponding kep maps. In table 5.1 the values of kep during air 
breathing and the hypercapnic hyperoxia induced change in kep are listed for all 
patients. The standard deviation of the average value of kep in table 5.1 reflects both 
the heterogeneity of the tumour and the measurement error including motion 
artifacts. Both small decreases and increases in the Gd-DTPA uptake rate were 
found as a result of breathing the hyperoxic hypercapnic gas mixture but none were 
statistically significant (Student's t-test, p>0.05). There was a mean increase in Gd- 
DTPA uptake rate in the tumour of all patients of 2.2% (± 9%), which was also not 
statistically significant (ANOVA, split plot design; p=0.54). In the distribution
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histograms of kep values no evident changes in the profile of Gd-DTPA uptake rates 
were observed visually.
The gradient-echo MR images were used to reconstruct maps of R2* (R2*=1/T2*), 
as is shown in figure 5.1d. On images recorded during air breathing the tumour was 
selected and values of the T2* of the tumour were calculated. After switching to 
breathing the hyperoxic hypercapnic gas mixture, data obtained in the first minute 
was discarded to allow oxygen levels in blood to reach a new equilibrium. The 
remaining R2* maps were processed as those obtained during air breathing. Table 
5.2 lists the average values of T2* in the tumour during air breathing and the change 
in T2* due to breathing the gas mixture. In all patients an increase in T2* was 
observed, which was statistically significant in 7 out of 11 cases (Student's t-test, 
p<0.05). The mean increase in T2* in the tumour of all patients was 5.5% (± 2.6%) 
which was highly significant (ANOVA, split plot design; p<0.001).
patient T2* (air) (ms) A
 
—
1 
2 * (%)
1 29.1 ± 1.8 8.2 ± 2.9 *
2 31.1 ± 2.0 0.6 ± 2.5
3 32.5 ± 2.8 6.9 ± 3.4
4 26.9 ± 0.9 7.5 ± 1.9 ♦
5 37.3 ± 1.5 5.9 ± 1.2 ♦
6 38.2 ± 1.1 6.1 ± 1.6 ♦
7 31.1 ± 2.1 5.9 ± 2.0 *
8 36.6 ± 2.6 7.9 ± 3.5 *
9 34.2 ± 2.7 7.4 ± 6.7
10 37.2 ± 1.3 3.1 ± 1.3 *
11 45.2 ± 3.2 1.4 ± 2.3
Table 5.2. Values of T2* in the tumour during air breathing and the change due to breathing the 
hyperoxic hypercapnic gas mixture. Values are presented as mean ± standard deviation. AT2* = 
T2*(hyperoxic hypercapnic gas mixture) - T2*(air), expressed as % with respect to T2*(air). In 7 out 
of 11 patients the hypercapnic hyperoxia induced increase in T2* was statistically significant 
(Student's t-test, * p<0.05, ♦ p<0.01).
To assess this increase in the value of T2* due to breathing the hyperoxic 
hypercapnic gas mixture in more detail histograms of T2* were created of all pixels 
in the tumour region. In figure 5.2 the T2* histogram of the tumour of the same 
patient as in figure 5.1 is shown. Values of T2* shorter than 20 ms could not be 
calculated. In particular the high values of T2* seem to be more abundant in the 
data recorded during breathing the gas mixture. This phenomenon was observed in 
all patients and may account for the hypercapnic hyperoxia induced increase in the 
average value of T2*.
The results in table 5.1 and 5.2 show significant differences between patients in 
both the Gd-DTPA uptake rate and the value of T2* (ANOVA, split plot design; both
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p<0.001). Correlations between the values of T2* and kep were not found (Pearson 
correlation, p>0.05). Also, pixelwise matching of the R2* map and the kep map did 
not lead to a strong correlation in any of the patients (Pearson's correlation 
coefficient<0.3).
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Figure 5.2. The T2* histogram of the tumour of the same patient as shown in figure 5.1, visualising 
the distribution of values of T2* (ms) during air breathing and breathing the hyperoxic hypercapnic 
gas mixture.
Discussion
Most other work on the effects of breathing hyperoxic hypercapnic gas mixtures on 
tumour oxygenation and vascularity has been done in laboratory animals using 
carbogen gas (95% O2 + 5% CO2). Due to the high CO2 content carbogen is difficult 
to breathe for patients during the prolonged time necessary to acquire the MRI data. 
In our experience the hyperoxic gas mixture containing 2% CO2 is better tolerated 
by most patients. Near infrared spectroscopy studies in mice showed that the 
oxyhaemoglobin / deoxyhaemoglobin ratio significantly increases when breathing 
the 2% CO2 hyperoxic gas mixture compared to air breathing. This ratio remains 
nearly constant however when the CO2 content is increased to 5%, suggesting that 
the gas mixture containing 2% CO2 and 98% O2 is sufficient for maximum 
oxygenation (13). This was also shown by blood gas analyses in rats breathing 
different hyperoxic hypercapnic gas mixtures (36). Furthermore, radiosensitisation in 
mice was shown not to be affected by reduction of the CO2 content from 5% even to 
1% (37).
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Tumour blood oxygen levels were assessed using multiple gradient-echo BOLD 
MRI. Although the BOLD effect may not only be governed by the oxygenation status 
but also by flow effects (38-40), measuring the value of T2* with a multiple echo 
sequence is thought to be quite insensitive for flow (41). Thus, multiple gradient­
echo MRI may be an important tool for the assessment of the local oxygenation 
status. Measurement of pretreatment oxygenation levels using oxygen electrodes 
already showed to be predictive of radiation response in both head and neck 
carcinomas and carcinomas of the uterine cervix (42,43).
Breathing a hyperoxic hypercapnic gas mixture causes a dramatic increase in the 
concentration of dissolved oxygen in the plasma and a decrease in the amount of 
deoxyhaemoglobin (11,13,44). This decrease of the deoxyhaemoglobin 
concentration is reflected in an increase of T2* (20). The T2* increase of 5.5%, as 
observed in this study, may represent a much larger change in deoxyhaemoglobin 
concentration, as other factors such as local magnetic field inhomogeneities and 
tissue structure also contribute to the basal value of T2*. Apart from blood 
oxygenation, the deoxyhaemoglobin concentration is also sensitive to blood volume 
and haematocrit. A variable response to hypercapnia and hyperoxia was observed 
in vessel diameters and haematocrit in laboratory animal models (14). However, 
BOLD MRI signal intensity correlated significantly with the fraction of oxygenated 
haemoglobin (14) and the effect of hyperoxic conditions on blood volume was 
shown to be inferior to the blood oxygenation increase (45). Thus, the decrease in 
deoxyhaemoglobin concentration suggests a substantial increase in blood pO2 in 
head and neck tumours due to breathing a hyperoxic hypercapnic gas mixture. The 
question remains whether this is a good representation of tumour tissue pO2, which 
is dependent on both oxygen supply and consumption. Information on the way 
microregional oxygen gradients are affected by hyperoxygenation is still limited. 
However, Al Hallaq et al (29) showed the carbogen-induced increase in T2* to be 
strongly correlated with increased tumour pO2 levels, as measured in rats using 
oxygen micro-electrodes. Thus, changes in the value of T2* may provide information 
about tumour oxygen levels during breathing of a hyperoxic hypercapnic gas 
mixture.
While arterial blood may have a much longer T2* than generally found in tissue, in 
venous blood the T2* may be as short as 12 ms (46). In the T2* histogram of the 
tumour (figure 5.2) the higher values of T2* during breathing of the hyperoxic 
hypercapnic gas mixture may reflect well-perfused regions containing blood with low 
deoxyhaemoglobin levels. One might expect that capillaries and small vessels 
during air breathing contain blood with oxygen levels somewhere between arterial 
and venous blood levels, although in tumours large heterogeneity in 
oxyhaemoglobin levels may be present (47). If in capillaries more haemoglobin 
remains oxygenated because of the high amount of dissolved oxygen in the plasma 
during breathing the hyperoxic hypercapnic gas mixture, the T2* values
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corresponding to these vessels will increase. Thus, presenting data as histograms 
allows investigation of tumour heterogeneity, both with respect to baseline values 
and hypercapnic hyperoxia induced changes. This may be important information for 
the selection of treatment strategies and prediction of treatment response.
Dynamic Gd-DTPA contrast enhanced MRI was used to study changes in tumour 
vascularity. This method already showed to be of value as a predictor of response to 
radiotherapy for head and neck tumours (48). In this study, contrast enhancement 
data was analysed using a physiological pharmacokinetic model (35), resulting in 
values of the rate of Gd-DTPA uptake. This contrast medium uptake rate is 
dependent on multiple physiological factors, including tumour blood flow, volume of 
extravascular extracellular space, vascular surface area and permeability (34,35). In 
general there is insufficient physiological information to establish which of these 
factors mainly governs the rate of Gd-DTPA uptake. Thus, changes in the uptake 
rate during breathing a hyperoxic hypercapnic gas mixture may only become 
manifest if substantial vascular changes occur.
In most laboratory animal models oxygen levels measured in tumour tissue and 
blood increased dramatically during carbogen breathing as measured either 
polarographically or by blood gas analysis (e.g. 12,13,30,49), although non­
significant changes have also been observed (e.g. 50). A heterogeneous response 
of tumour blood flow to breathing hyperoxic hypercapnic gas mixtures has been 
reported (e.g. 12,13,40), probably reflecting the variable types of tumours and 
tumour-host interactions. While increases in tumour blood flow are usually explained 
in terms of vasodilatation, decreases in tumour blood flow can be explained by the 
steal effect, which may occur when the tumour vascular bed runs in parallel to the 
vasculature of the host. Also vasoconstriction of tumour vasculature and reduced 
tumour blood flow in response to carbogen breathing have been reported (14, 51). It 
is difficult however to extrapolate these results directly to primary tumours in 
humans, because in humans the relationship between tumour and normal tissue 
vasculature may be fundamentally different.
The results of the present study show no apparent change in tumour vascularity 
(table 5.1) as measured by the dynamic Gd-DTPA contrast uptake rate. This implies 
that a dramatic hypercapnic hyperoxia induced decrease of blood flow, which could 
be disadvantageous for therapy, did not occur. In the ARCON therapy breathing the 
hyperoxic hypercapnic gas mixture is combined with administration of nicotinamide 
(5,7,52). This vasomodulator has been shown to improve radiosensitivity by 
enhancing tissue microcirculation (53-55). The effect of nicotinamide on tumour 
vascularity was not investigated in this study. In several human tumours carbogen 
breathing was shown to induce no overall change in blood flow and only small 
transient fluctuations in individual tumour blood flow, as measured by laser Doppler
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flowmetry (15). When combining carbogen with nicotinamide however, tumour blood 
flow did increase (56).
The present results indicate that in head and neck tumours the primary mechanism 
of action of breathing the hyperoxic hypercapnic gas mixture is an improvement of 
the tumour blood oxygenation level which may result in a reduction of hypoxia. In 
healthy volunteers, analysis of arterial blood samples showed a slight increase in 
the oxygen saturation of haemoglobin and a large increase in blood pO2 (11). In 
head and neck tumours oxygen tension increased during carbogen breathing, as 
was shown using oxygen electrodes (57). Using the comet assay a reduction in the 
hypoxic fraction in response to breathing different hyperoxic hypercapnic gas 
mixtures was found in hypoxic tumours (58). This was also shown in hypoxic marker 
studies (vascular architecture and microenvironmental parameters, VAMP) using 
laryngeal squamous cell carcinoma xenografts, in which carbogen breathing 
reduced diffusion limited hypoxia (9,59).
In conclusion, breathing a hyperoxic hypercapnic gas mixture was shown to improve 
tumour blood oxygenation in patients with head and neck tumours, which may 
contribute to the success of the ARCON therapy. No substantial changes in overall 
tumour vascularity were found, as measured by the Gadolinium-DTPA contrast 
uptake rate in the tumour. MRI enables non-invasive investigation of both tumour 
blood oxygenation and vascularity and may assist in the prediction of response to 
treatments using hyperoxygenation for other tumour types as well.
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Abstract
Because meningiomas tend to recur after (partial) surgical resection, radiotherapy is 
increasingly being applied for the treatment of these tumours. Radiation dose levels 
are limited however to avoid radiation damage to the surrounding normal tissue. The 
radiosensitivity of tumours can be improved by increasing tumour oxygen levels. 
The aim of this study was to investigate if breathing a hyperoxic hypercapnic gas 
mixture could improve the oxygenation of meningiomas, as monitored by BOLD 
MRI. In addition, dynamic Gd-DTPA contrast enhanced MRI was used to assess 
changes in tumour vascularity under hyperoxic hypercapnic conditions. Ten 
meningioma patients were each studied twice; without and with breathing a gas 
mixture consisting of 2% CO2 and 98% O2. Values of T2* and the Gd-DTPA uptake 
rate kep were calculated under both conditions. In six tumours a significant increase 
in the value of T2* in the tumour was found, suggesting an improved tumour blood 
oxygenation, which exceeded the effect in normal brain tissue. Contrarily, two 
tumours showed a significant T2* decrease. The change in T2* was found to 
correlate with both kep and with the change in kep. The overall effect of hypercapnic 
hyperoxia on meningiomas will be a balance between oxygenation and vascular 
effects. Improved oxygenation of blood entering the tumour may be counteracted by 
a reduction in tumour blood volume and flow. The current MRI protocol may assist in 
radiation treatment selection in patients with meningiomas.
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Introduction
Meningiomas account for 15-20% of all intracranial tumours (1,2). Most of these 
tumours are benign, but within this group great variations in cellular morphology, 
architectural pattern, vascularity, and metaplastic changes have been described 
(1,3). MRI has been frequently used to identify and characterise meningiomas. 
Hyperintensity, isointensity and hypointensity on T1 and T2 weighted images have all 
been reported and data on correlations between MR signal intensity and histological 
features is still controversial (3-5). Also the presence of oedema is highly variable 
from one meningioma to another (2). With Gadolinium-DTPA (Gd-DTPA) infusion, 
meningiomas usually show clear contrast enhancement, sharply demarcating the 
tumour from normal brain tissue (5).
The first choice of treatment for meningiomas is surgical resection, occasionally in 
combination with preoperative embolisation (5). However, meningiomas often recur, 
even after macroscopic total removal (6,7). Recently, there has been an increased 
interest in stereotactic radiosurgery and radiotherapy for the treatment of 
meningiomas in which complete resection is impossible (8,9). Although in general 
there is a good response to radiotherapy, sometimes higher doses of radiation are 
needed to improve control rates (6). Radiation dose levels are limited however to 
avoid radiation damage to the normal central nervous system (6,10). The radio­
sensitivity of tumours can be improved by increasing tumour oxygen levels (11). 
This may be achieved by breathing high oxygen content gases, which have been 
shown to improve oxygenation in several human tumours (12,13). For head and 
neck tumours, breathing a hyperoxic hypercapnic gas mixture like carbogen in 
combination with nicotinamide administration resulted in a significantly improved 
tumour response to accelerated radiotherapy (Accelerated Radiotherapy with 
Carbogen and Nicotinamide, ARCON, 14). Preliminary results of breathing a 
hyperoxic hypercapnic gas mixture to increase tumour blood oxygenation in 
meningiomas already seemed promising (15). Hyperoxic hypercapnic conditions 
during radiotherapy might allow optimisation of radiation schemes.
The effects of breathing hyperoxic hypercapnic gas mixtures on tumour oxygenation 
and blood flow can be studied noninvasively by MRI (16). Changes in oxygenation 
can be measured by blood oxygen level dependent (BOLD) MR imaging, using the 
paramagnetic deoxyhaemoglobin as an endogenous contrast agent (17). Deoxy­
haemoglobin shortens the MR time constant for the transverse magnetisation decay 
(apparent spin-spin relaxation time, T2*), which can be assessed by gradient-echo 
MRI. BOLD T2* measurements have been shown to correlate with tumour pO2 levels 
and deoxyhaemoglobin concentration in laboratory animal models (18,19). Tumour 
blood flow may respond heterogeneously when challenged with a hyperoxic 
hypercapnic gas mixture. The vasodilatory effect of CO2 may be dependent on the 
association of blood vessels with smooth muscle cells (18,20). In this respect, also
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the 'steal' effect is well-recognised: blood flow may be increased locally at the 
expense of an adjacent location, depending on the tumour vascular bed (20). 
Changes in blood flow, vascular volume, and permeability, can be studied by 
dynamic Gd-DTPA contrast enhanced MRI. This technique is widely used for the 
assessment of human tumours both in detection, identification, and staging.
The aim of this study was to investigate the effects of breathing a hyperoxic 
hypercapnic gas mixture on the oxygenation of meningiomas using BOLD MRI. In 
addition, dynamic Gd-DTPA contrast enhanced MRI was used to assess changes in 
tumour vascular function under hyperoxic hypercapnic conditions. This MRI protocol 
may assist in the selection of appropriate meningioma patients for radiation 
treatment using hyperoxygenation.
Methods
Ten meningioma patients (3 males, 7 females) were included in the study. The 
mean age was 54 years (table 6.1). Approval for the study was obtained from the 
local ethics committee and informed consent was obtained from all patients. MR 
imaging was performed on a 1.5 T Siemens Vision whole body system using a CP- 
head coil. All patients were studied twice; without and with breathing a gas mixture 
consisting of 2% CO2 and 98% O2. Gadolinium-DTPA was administered by 
intravenous bolus injection (6 ml, 0.5 M, 1 ml/s).
sex age tumour location histological
subtype*
tumour 
volume (ml)
oedema 
volume (ml)
1 f 48 convexity cerebellar n.a. 10.5 0.0
2 m 63 convexity parietal n.a. 9.3 0.0
3 f 70 convexity parieto-occipital microcystic 29.9 37.5
4 f 45 convexity frontal meningothelial 22.4 19.1
5 f 43 posterior fossa meningothelial 20.1 0.0
6 f 49 sphenoid wing meningothelial 16.2 102.6
7 f 55 convexity parietal transitional 58.3 0.0
8 m 68 olfactory groove transitional 64.8 66.4
9 f 50 parasagittal hemangioblastic 30.9 109.1
10 m 51 lateral ventricle atypical 7.9 50.7
Table 6.1. Clinical and tumour related data of the meningioma patients. *n.a.: data not available.
In the first session Gd-DTPA tissue uptake was monitored (FLASH, TR=50 ms, 
TE=4.4 ms, 7 mm slice) while the patient was breathing air. In the second session 
gradient-echo images (2D FLASH, TR=65 ms, 16 echoes, TE=6-51 ms, 5 mm slice) 
were recorded continuously for 8-10 minutes whilst breathing air, then breathing of 
the hyperoxic hypercapnic gas mixture was started and images were recorded for
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another 5-8 minutes, followed by Gd-DTPA contrast enhanced imaging as in the first 
session. Altogether, patients had to breathe the hyperoxic hypercapnic gas mixture 
for 12 minutes. The time between the two sessions was one week.
T2* values (ms) were calculated pixelwise from the gradient-echo imaging data and 
displayed as a map. The value of T2* of the tumour under normal and hyperoxic 
hypercapnic conditions was obtained by averaging all pixels within the selected 
tumour region. Also, the change in T2* during hypercapnic hyperoxia was calculated 
for normal brain tissue on the contralateral side of the brain. As air leaks might occur 
in the experimental setup while supplying the hyperoxic hypercapnic gas mixture, 
patients were checked for inhaling the gas mixture properly. For this purpose the T2* 
of venous blood was measured in the transverse sinus or the sagittal sinus. If no 
statistically significant (Student's t-test, p<0.05) increase in the T2* of venous blood 
was observed during breathing of the hyperoxic hypercapnic gas mixture the 
measurement was considered a technical failure. Changes in T2* were expressed 
as AT2* (ms) = T2*(hyperoxic hypercapnic gas mixture) - T2*(air).
The dynamic Gd-DTPA contrast image data was analysed as described by 
Rijpkema et al (21). Using a physiological pharmacokinetic model the rate of 
contrast medium uptake (kep (min-1)) was determined. In perfused tumour tissue this 
Gd-DTPA uptake rate reflects physiological parameters such as vascular 
permeability, vascular surface area and tumour blood flow (22). Maps of kep were 
reconstructed from the value of kep for each pixel. The geometric mean of the Gd- 
DTPA uptake rates under normal and hyperoxic hypercapnic conditions was 
calculated after log transformation of all pixel values in Gd-DTPA enhancing regions 
of the tumour. Changes in kep were represented as Akep = kep(hyperoxic hypercapnic 
gas mixture) - kep(air), expressed as % with respect to kep(air). Statistically 
significant differences were shown using Student's t-test. Pearson's correlation 
coefficient was used to assess significant correlations.
Results
Ten patients successfully completed the entire MRI protocol. From the twelve 
initially selected patients, two dropped out of the study because no significant 
increase in the value of T2* in the transverse sinus was observed during breathing of 
the hyperoxic hypercapnic gas mixture and the measurement was considered a 
technical failure. A transversal turbo inversion recovery (with magnitude 
reconstruction) image of a patient with a meningioma located in the right 
hemisphere is shown in figure 6.1a. Dynamic Gd-DTPA uptake was monitored in a 
series of images at 2 second intervals for 90 seconds. The last image of this series 
is displayed in figure 6.1b, showing signal enhancement in the tumour region. This 
contrast enhanced MRI data was used to reconstruct maps of the rate of contrast
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agent uptake, kep, as shown in figure 6.1c for the same patient. The average values 
of the Gd-DTPA uptake rate of the tumour during air breathing and breathing the 
hyperoxic hypercapnic gas mixture were calculated from the corresponding kep 
maps. Large variations were found in the values of kep between meningiomas, 
ranging from 0.24 to 3.11 min-1 (mean 1.21 min-1). Changes in the Gd-DTPA uptake 
rate as a result of breathing the hyperoxic hypercapnic gas mixture were diverse. In 
three tumours an increase in kep was found, while in seven tumours kep decreased. 
The average Akep was 1% (range -57 to +89%).
Figure 6.1. Transversal MR images of a patient with a meningioma in the right hemisphere. R: right, 
A: anterior. (a) Turbo inversion recovery (with magnitude reconstruction) image clearly showing the 
tumour. (b) T1 weighted image recorded 90 seconds after Gd-DTPA contrast administration during 
breathing a hyperoxic hypercapnic gas mixture consisting of 2% CO2 and 98% O2. (c) Map showing 
the Gd-DTPA uptake rate, as calculated from the dynamic Gd-DTPA enhanced data. (d) The R2* 
map (R2*=1/T2*) calculated from the BOLD MRI data recorded during breathing of the hyperoxic 
hypercapnic gas mixture.
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Figure 6.2. Graph showing the T2* changes in blood, tumour tissue, and contralateral brain tissue 
during hypercapnic hyperoxia. Breathing of the hyperoxic hypercapnic gas mixture was started after 
8.5 minutes of air breathing. In the sagittal sinus the value of T2* increased significantly in all patients 
during breathing of the hyperoxic hypercapnic gas mixture, indicating an improved blood 
oxygenation. This is shown here in grey squares for patient A. Contralateral brain tissue (triangles) 
showed a slight T2* increase of 2 ms in this patient. In the tumour (tumour A, open circles) an 
increase was observed in T2*. Contrarily, the tumour of another patient (tumour B, black circles) 
showed a decrease in T2* under hyperoxic hypercapnic conditions.
The T2* weighted MR images were used to reconstruct maps of R2* (R2*=1/T2*), as 
is shown in figure 6.1d. The basal values of T2* however reflect not only tumour 
characteristics such as oxygenation and vascular and tissue architecture, but also 
local homogeneity of the magnetic field, especially when proximal to sinuses in the 
head. Therefore, only the change in T2* was evaluated. T2* maps obtained in the 
first minute after switching to breathing the hyperoxic hypercapnic gas mixture were 
discarded to allow oxygen levels in blood to reach a new equilibrium. Under 
hyperoxic hypercapnic conditions all patients showed a statistically significant 
increase of the value of T2* in either the sagittal or the transverse sinus relative to 
air breathing. In six tumours also a significant increase in the average value of T2* in 
the tumour was observed, suggesting an improved tumour blood oxygenation. 
Contrarily, two tumours showed a significant T2* decrease and in two tumours no 
statistically significant change in T2* was observed. The average AT2* over all 
tumours was 3.7 ms (range -1.9 to +11.3 ms). Normal brain tissue measured on the 
contralateral side of the brain showed a small but significant T2* increase in all 
patients due to breathing the hyperoxic hypercapnic gas mixture, with a mean 
increase of 2.3 ms (standard deviation 0.6 ms). In figure 6.2 the T2* changes in 
venous blood and contralateral brain tissue during hypercapnic hyperoxia are shown
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for one patient. The T2* versus time plots of a tumour region that showed a T2* 
increase and a tumour region that showed a T2* decrease under hyperoxic 
hypercapnic conditions are also shown.
15-,
a
b
Figure 6.3. (a) Graph showing the correlation of the Gd-DTPA uptake rate kep during air breathing 
with the hypercapnic hyperoxia induced change in T2* in meningiomas. The correlation was highly 
significant (Pearson's r=-0.88, p=0.001). (b) The change in kep due to breathing the hyperoxic 
hypercapnic gas mixture showed a moderate correlation with the change in T2* in tumour tissue 
(Pearson's r=0.69, p=0.024).
Interestingly, correlations were found between the change in T2* and the (change in) 
Gd-DTPA uptake rate. The change in T2* was found to correlate negatively with kep, 
with a Pearson's correlation coefficient of -0.88 (p=0.001, figure 6.3a). Thus, 
tumours with a high Gd-DTPA uptake rate tend to show a negative T2* response to 
hypercapnic hyperoxia. The change in kep correlated positively with the change T2* 
(Pearson's r=0.69, p=0.024, figure 6.3b). Consequently, a negative correlation was 
found between kep and Akep (Pearson's r=-0.79, p=0.007, data not shown), indicating 
that in tumours with a high Gd-DTPA uptake rate the uptake is decreased during 
hypercapnic hyperoxia compared to normal conditions. No statistically significant 
correlations were found with patient's age, histological subtype of the tumour,
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volume of the tumour, volume of oedema, the basal value of T2*, or the T2* increase 
in contralateral normal brain tissue.
Discussion
Tumour oxygenation is mainly influenced by the arterial oxygen supply to the tissue, 
which depends on arterial oxygen content and tissue perfusion (23). Increasing the 
arterial pO2 by breathing a hyperoxic hypercapnic gas mixture should therefore 
improve the O2 diffusion from microvessels to the cells (24). However, tumour 
vasculature may exhibit structural and functional abnormalities and blood flow 
through tumours is anything but uniform (20). Most tumours show an increased 
tumour oxygenation in response to breathing hyperoxic hypercapnic gas mixtures 
(1-5% CO2, 99-95% O2), but also decreased tumour oxygenation has been reported 
in various human tumours (13,25). The impact of hypercapnic hyperoxia on blood 
flow may also be heterogeneous. In laboratory animal models vascular effects 
including vasodilation, vasoconstriction, steal phenomena, and blood pressure 
changes have been observed (18,20,26-28). The effects of breathing a hyperoxic 
hypercapnic gas mixture on tumour blood oxygenation and blood flow have been 
assessed by MRI in both laboratory animal models and humans. Although most 
studies show a clear increase in T2* under hyperoxic hypercapnic conditions, also 
non-significant changes have been reported (16,18,28-30).
In meningiomas, blood flow and oxygenation may show large variations. Using 
orthogonal polarisation spectral imaging, meningiomas were characterised by 
chaotic and dilated vessels with almost no erythrocyte movement (31). A striking 
architectural feature of meningiomas was that sections in which vessels were 
tortuous and close together were adjacent to sections in which no vessels were 
present (31). Using contrast enhanced MRI and CT, blood flow and blood volume 
were found to be highly variable (32,33). The same was found for the arterial blood 
supply and degree of vasodilation, as assessed by angiographic techniques (5,34). 
Although meningiomas are in general well vascularised, dynamic contrast enhanced 
MRI showed variations in Gd-DTPA uptake rates similar to the results of the present 
study (35,36). No correlation was found between the degree of contrast 
enhancement and histopathological features, vascularity, or consistency of 
meningiomas (3,4). Haemoglobin concentration showed high interindividual 
variability in meningiomas and saturation ranged from 10-40%, as measured by NIR 
reflection measurements (37).
One could expect that breathing a hyperoxic hypercapnic gas mixture results in an 
increase in T2*, as observed in e.g. head and neck tumours (16). Blood entering the 
tumour will be better oxygenated, resulting in a decrease of the deoxyhaemoglobin 
concentration under hyperoxic hypercapnic conditions. The Gd-DTPA uptake rate
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may either remain constant or increase under these conditions, because of a 
potential CO2 induced increase in blood volume and flow (23,38). These effects on 
T2* and kep were observed in most of the meningiomas in this study (see figure 
6.3b). All of these tumours however had a relatively low Gd-DTPA uptake rate 
(figure 6.3a), suggesting no extremely high vascular permeability, blood volume, or 
flow. As these meningiomas showed a larger increase in T2* than normal brain 
tissue, the combination of radiotherapy with hyperoxygenation may be a treatment 
option for these patients to improve radiation response (15). However, in some 
patients also an opposite effect was observed. Meningiomas with a relatively high 
Gd-DTPA uptake rate showed a decrease in T2* (figure 6.3a), suggesting a 
worsened tumour blood oxygenation. In these tumours also a decrease in the Gd- 
DTPA uptake rate was found under hyperoxic hypercapnic conditions. This may be 
explained by a steal effect as a result of the CO2 induced vasodilation in the 
surrounding normal tissue (20,23), which may cause reduction of tumour blood flow 
and a further desaturation of the blood (28,39). Also, tumour blood volume may 
decrease as a result of vascular collapse (28). Because many tumour blood vessels 
have weak walls (20,40), they may collapse if blood pressure is reduced. Especially 
those meningiomas with a high interstitial pressure due to highly permeable vessels 
(resulting in a high Gd-DTPA uptake rate) may show this phenomenon. Assuming 
that no substantial changes in oxygen consumption occur under hyperoxic 
hypercapnic conditions, a decrease in both blood flow and blood volume may result 
in a decrease of tumour blood oxygenation (23,28).
The overall effect of breathing a hyperoxic hypercapnic gas mixture on 
meningiomas will be a balance between oxygenation and vascular effects. In some 
tumours the improved oxygenation of blood entering the tumour may be the 
dominant effect, while in others reduced tumour blood volume and flow may 
counteract this result. All these effects may contribute to the response of tumours to 
hypercapnic hyperoxia. In 6 out of 10 meningioma patients, hypercapnic hyperoxia 
was shown to induce an improved tumour blood oxygenation exceeding the effect 
on normal brain tissue, a prerequisite to consider radiotherapy combined with 
hyperoxygenation. The presence of both vascular effects and oxygenation effects 
and the heterogeneous response to hypercapnic hyperoxia necessitates individual 
assessment of the effects of breathing a hyperoxic hypercapnic gas mixture on 
meningiomas. Thus, BOLD MRI and dynamic contrast enhanced MRI may guide 
treatment selection for patients with meningiomas.
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Abstract
Oligodendroglial tumours may not be distinguished easily from other brain tumours 
based on clinical presentation and MRI alone. Identification of these tumours 
however may have therapeutical consequences. The purpose of this study was to 
characterise and identify oligodendrogliomas by their metabolic profile as measured 
by 1H MR Spectroscopic Imaging (MRSI). Fifteen patients with oligodendroglial 
tumours (8 high grade oligodendrogliomas, 7 low grade oligodendrogliomas) 
underwent MRI and short echo time 1H MRSI examinations. Five main metabolites 
found in brain MR spectra were quantified and expressed as ratios of tumour to 
contralateral white matter tissue. The level of lipids plus lactate was also assessed 
in the tumour. For comparison also six patients with a low grade astrocytoma were 
included in the study. The metabolic profile of oligodendrogliomas showed a 
decreased level of N-acetylaspartate and increased levels of choline containing 
compounds and glutamine plus glutamate compared to white matter. The level of 
glutamine plus glutamate was significantly higher in low grade oligodendrogliomas 
than in low grade astrocytomas and may serve as a metabolic marker in diagnosis 
and treatment planning. In high grade oligodendrogliomas large resonances of lipids 
plus lactate were observed in contrast to low grade tumours.
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Introduction
Oligodendrogliomas represent 5-18% of all intracranial gliomas and arise 
preferentially in the cortex and white matter of the cerebral hemispheres (1). The 
majority of oligodendrogliomas are low grade tumours (1,2). Based on clinical 
presentation, oligodendroglial tumours may not be distinguished easily from other 
brain tumours, especially from astrocytomas. Until recently, the identification of 
oligodendrogliomas among brain tumours did not have therapeutical consequences. 
However, with the recognition that oligodendrogliomas are uniquely sensitive to 
chemotherapy, differential diagnosis of these tumours has become increasingly 
important. Since Cairncross and McDonald observed that recurrent anaplastic 
oligodendrogliomas respond to chemotherapy (3), several groups have reported on 
the chemosensitivity of both high and low grade oligodendrogliomas and mixed 
oligoastrocytomas (4-7). As a result oligodendrogliomas are increasingly being 
treated with chemotherapy, in contrast to e.g. astrocytomas, which are substantially 
more resistant to chemotherapeutic agents (4-7).
In general brain tumours are pathologically diagnosed by analysis of tumour tissue 
obtained (invasively) by biopsy. Both Magnetic Resonance Imaging (MRI) and 1H 
Magnetic Resonance Spectroscopy (MRS) have proven to be powerful noninvasive 
tools for the characterisation of brain tumours (8). MRI is well-established in 
obtaining the anatomical localisation and extent of tumours. However, conventional 
MRI techniques are limited in the diagnosis of brain tumour type (9). Furthermore, 
MRI investigation of blood brain barrier damage using an extragenous contrast 
agent (e.g. Gadolinium-DTPA) cannot reliably differentiate oligodendroglial tumour 
grades. Low grade oligodendrogliomas may show contrast enhancement, while lack 
of contrast enhancement does not equate with low grade malignancy (10).
MR spectroscopy may provide additional information in cases in which the 
differential diagnosis of tumours by MRI is difficult (11). Metabolic information 
obtained by MRS has proven to be promising in the accurate diagnosis of human 
brain tumours (8,9,12) and the evaluation and monitoring of therapy (13,14). Most of 
these studies so far covered astrocytomas, the most common form of glial tumours. 
The aim of this study was to characterise oligodendrogliomas by their metabolic 
profile to enable specific identification of these tumours. For this purpose patients 
with high and low grade oligodendrogliomas were examined by short echo time 1H 
MRSI.
PATIENTS AND METHODS
Fifteen patients with histologically proven oligodendroglial tumours were included in 
this study. Four patients had mixed tumours (two low grade and two high grade
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oligoastrocytomas) with a predominant component of oligodendroglioma, which 
were categorised as oligodendrogliomas in this study. Seven tumours were 
pathologically characterised as low grade (WHO grade II) and eight as high grade 
oligodendroglial tumours (WHO grade III). For comparison also six patients with a 
low grade astrocytoma (WHO grade II) were included in the study. The age and sex 
distribution was comparable in all groups: male/female 5/2, age 39 ± 9; male/female 
5/3, age 45 ± 12; and male/female 5/1, age 41 ± 14, respectively. All patients were 
previously untreated and gave informed consent to participate in this study. 
Approval for the study was obtained from the local ethics committee.
MRI and MRS were carried out on a 1.5 T Siemens Vision system. After 
conventional T1 weighted, T2 weighted and PD weighted imaging, MR 
Spectroscopic Imaging (MRSI) was performed. MR spectra were recorded both with 
and without water suppression using a 16x16 2D STEAM MRSI sequence. 
Sequence parameters were TR 2500 ms, TE 20 ms, TM 30 ms, slice thickness 15 
mm, FoV 200 mm. The measurement time to obtain all MRSI data was ~30 minutes. 
After MR spectroscopy a bolus injection of Gadolinium-DTPA (Gd-DTPA) was 
applied and conventional T1 weighted images were recorded. In five patients this 
Gd-DTPA contrast enhancement was measured before the MR spectroscopy.
Processing of the MRSI data consisted of the following. A Hamming filter of 50% 
was applied in k-space before spatial Fourier transform using the LUISE software 
package (Siemens, Erlangen, Germany). Tumour MRSI voxels were selected from 
areas that showed Gd-DTPA contrast enhancement. If no contrast enhancement 
was seen MRSI voxels were selected from the T1 weighted and T2 weighted MR 
images. To obtain an internal standard, spectra of up to three voxels located in 
contralateral white matter were used for each patient. All spectra were analysed by 
LCModel (15). The main metabolites NAA (N-acetylaspartate plus N- 
acetylaspartylglutamate), Cr (creatine plus phosphocreatine), Cho (choline 
containing compounds), Ino (myo-inositol), and Glx (glutamine plus glutamate) were 
quantified and expressed as ratio of tumour to contralateral white matter. In the 
spectral region around 1.3 ppm both lactate and lipids were assessed by LCModel. 
The lipid signal was quantitated as a single peak at 1.3 ppm. Since the use of a 
short echo time (20 ms) generally does not allow accurate differentiation between 
signal contributions from lipids and lactate in this spectral region, the metabolite 
levels of both compounds were summed. All statistical analyses were performed 
using Student's t-test (two-sided).
Results
All twenty-one patients included in this study successfully completed the MRI and 
MRSI protocol. In 8 patients (2 low grade oligodendrogliomas, 2 high grade
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oligodendrogliomas, 4 astrocytomas) no Gd-DTPA contrast enhancement was 
observed in the tumour and the conventional T1 weighted and T2 weighted images 
were used to delineate the tumour. Sagittal and transversal MR images of a patient 
with a low grade oligodendroglioma are shown in figure 7.1. The grid indicating the 
position of the MRSI voxels is plotted on these images. To characterise the tumour 
by its metabolic profile a voxel in the tumour was selected on the Gd-DTPA 
enhanced image (figure 7.1c, marked square). The corresponding spectrum is 
shown in figure 7.2b. Contralaterally located white matter voxels were carefully 
selected to avoid contribution from white matter abnormalities that were observed 
on the MR images of some patients. In figure 7.2a the spectrum from white matter 
(figure 7.1b, marked square) is displayed. A spectrum from a high grade 
oligodendroglioma is shown in figure 7.2c.
Figure 7.1. MR images of a patient with a low grade oligodendroglioma in the right hemisphere. The 
grid indicates the position of the MRSI voxels. (a) Sagittal localiser image. (b) Transversal PD 
weighted image. (c) Transversal T1 weighted image after Gd-DTPA administration, displaying the 
tumour as a hypointense region with slight Gd-DTPA contrast enhancement (hyperintense). The 
marked square on the PD weighted image (b) indicates the location from which the white matter 
spectrum in figure 7.2a was obtained; the marked square on the T1 weighted contrast enhanced 
image (c) indicates the location from which the tumour spectrum in figure 7.2b was obtained.
tumour / WM
NAA 0.45 ± 0.17 **
Cho 1.88 ± 0.99 **
Cr 0.82 ± 0.32
Ino 1.28 ± 0.69
Glx 1.38 ± 0.39 **
Table 7.1. Ratios of the five main metabolites found in all oligodendrogliomas (n=15) relative to white 
matter. Numbers are mean ± standard deviation. WM = white matter. ** Tumour versus white matter, 
p<0.01.
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Figure 7.2. 1H MR spectra obtained from short echo time STEAM MRSI (TR 2500, TE 20 ms) data 
sets. (a) Spectrum from white matter with peak assignments to NAA, Cr, Cho, Ino and Glx. (b) 
Spectrum from a low grade oligodendroglioma featuring a decreased level of NAA and increased 
levels of Cho and Glx compared to white matter. (c) Spectrum from a high grade oligodendroglioma 
showing large lipid and lactate resonances.
i-------------1-------------1-------------1-------------1-------------1-------------1
3.5 3.0 2.5 2.0 1.5 1.0 0.5
ppm
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a oligodendroglioma astrocytoma b oligodendroglioma oligodendroglioma
Figure 7.3. Scatter plots showing the distribution of metabolite levels for all patients. (a) Glutamine 
plus glutamate levels for low grade oligodendrogliomas and low grade astrocytomas. (b) Lipid plus 
lactate levels for low grade and high grade oligodendrogliomas. The mean of the corresponding 
metabolite levels is indicated in both figures.
All spectra were analysed and the tissue levels of the main metabolites NAA, Cr, 
Cho, Ino, and Glx were normalised to white matter levels for each patient. The 
results are shown in table 7.1 for all oligodendrogliomas. Besides a metabolic profile 
generally observed in brain tumours (decreased level of NAA and increased level of 
Cho) also a significant increase in Glx was found in oligodendroglial tumours.
Comparison of low grade oligodendrogliomas with low grade astrocytomas showed 
that Glx was significantly higher in oligodendrogliomas (table 7.2). The distribution of 
individual glutamine plus glutamate levels for low grade tumours is shown in figure 
7.3a.
Within the group of oligodendrogliomas, no significant difference was found between 
low grade tumours and high grade tumours in any of the main metabolites (table 
7.2). Interestingly, the relative level of all of these metabolites was lower in high 
grade tumours than in low grade tumours. The signal intensity of lipids plus lactate 
did differentiate low grade from high grade tumours significantly (p<0.01, table 7.2). 
In figure 7.3b a plot is shown visualising the distribution of lipid plus lactate levels for 
both low grade and high grade oligodendrogliomas.
Discussion
A common observation in 1H MR spectroscopy of glial tumours is a decreased level 
of NAA and an increased level of Cho. NAA is a major brain metabolite involved in 
cell signalling, regulation of interactions of brain cells, and the establishment and 
maintenance of the nervous system (16). The presence of NAA is used increasingly
111
C h a p t e r  7
in clinical MRS studies as a neuronal marker, although mature oligodendrocytes 
have also been shown to express NAA in vitro (17) Elevated Cho levels are 
consistent with an increased choline turnover in relation to membrane biosynthesis 
by proliferating cells (11). In this study both a decreased level of NAA and an 
increased level of Cho were found, in concordance with the general metabolic 
profile of glial tumours (8,18).
low grade low grade high grade
astrocytoma oligodendroglioma oligodendroglioma
(tumour / WM) (tumour / WM) (tumour / WM)
NAA 0.47 ± 0.16 0.51 ± 0.17 0.40 ± 0.16
Cho 1.99 ± 0.88 2.20 ± 1.08 1.60 ± 0.87
Cr 0.92 ± 0.25 0.97 ± 0.33 0.70 ± 0.26
Ino 1.44 ± 0.64 1.59 ± 0.54 1.01 ± 0.72
Glx 1.03 ± 0.22 1.48 ± 0.41* 1.30 ± 0.38
Lipids + lactate§ 3.9 ± 3.4 5.2 ± 2.4 24.7 ± 12.4#
Table 7.2. Ratios of the five main metabolites found in low grade astrocytomas, low grade 
oligodendrogliomas, and high grade oligodendrogliomas relative to white matter. Numbers are mean 
± standard deviation. WM = white matter. § The level of lipids plus lactate is expressed in arbitrary 
units, not as ratio to white matter. # High grade oligodendroglioma versus low grade 
oligodendroglioma, p<0.01. * Low grade oligodendroglioma versus low grade astrocytoma, p<0.05.
More strikingly, in the present study an increased level of Glx compared to white 
matter was found in oligodendrogliomas, which may differentiate these tumours 
from other glial tumours. Glutamate is the major excitatory transmitter in the human 
brain and its complex metabolic coupling between neurons and glial cells and 
interconversion to glutamine have been recognised (19-21). Comparison among the 
low grade tumours in this study demonstrated that Glx was the only metabolite 
measured that showed a statistically significant difference between 
oligodendrogliomas and astrocytomas (table 7.2). Although there is some overlap in 
the Glx levels of these tumours (see figure 7.3a), information on Glx levels can be 
used to assist in distinguishing low grade oligodendrogliomas from low grade 
astrocytomas. Distinction between these tumour types is important in diagnosis and 
treatment planning and usually cannot be made based on clinical presentation and 
MRI alone.
The potential role for elevated levels of Glx as a metabolic marker for 
oligodendrogliomas is supported further by in vitro NMR analyses of extracts of 
brain tumours. Tugnoli et al (22) described intense multiplets assigned to Glx as one 
of the main spectroscopic features in 1H MR spectra of low grade 
oligodendrogliomas. In the oligodendroglioma studied by Peeling et al (23) up to two 
times more Glx was found compared to other brain tumours (e.g. astrocytomas). 
Also, studies using cultured cells derived from nervous tissue showed a high level of 
Glx in oligodendrocytes and oligodendrocyte type 2 astrocyte progenitor (O-2A
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progenitor) cells compared to other neural cells such as astrocytes and neurons 
(24,25). Besides Glx, also alanine and glycine have been proposed by in vitro NMR 
studies and amino acid analyses to be useful as metabolic markers for 
oligodendrogliomas (24,26), but this could not be demonstrated in this study.
To the best of our knowledge, this study reports on the largest population of patients 
with oligodendroglial tumours assessed by 1H MRS, and is the first that used short 
echo time MRSI of these tumours. So far, in vivo MRS studies of 
oligodendrogliomas have used long echo times and focused mainly on NAA, Cho, 
and Cr. The metabolite concentrations in the tumour expressed as ratio to normal 
brain tissue were found to be 0.1-0.4 for NAA, 0.5-0.9 for Cr, and 1.4-1.9 for Cho 
(27,28), which is in agreement with the results of the present study (table 7.1). 
Tissue level ratios of Cho/Cr in oligodendrogliomas have been reported in the range 
of 0.3-1.6 (18,27,28). In this study a Cho(tumour)/Cr(tumour) ratio of 0.7 ± 0.3 was 
found (data not shown). Immunohistochemical studies demonstrated that this 
metabolite ratio parallels with the cell proliferation index for Ki-67 (MIB-1) positive 
cells (28); a parameter that was shown to be of prognostic relevance for patients 
with oligodendrogliomas (28,29).
In line with in vivo MRS, in vitro NMR analyses of surgically obtained tumour 
specimens of oligodendrogliomas show decreased levels of NAA and Cr, and an 
increased level of Cho compared to normal brain (22,23,27,30,31). Other metabolic 
features that have been described include an elevated level of Ino (22-24,32). In the 
present study an increase in Ino was found in oligodendrogliomas compared to 
white matter, but statistical significance could only be demonstrated in low grade 
tumours (p=0.03), not in the total group of oligodendrogliomas (p=0.14, table 7.1). In 
vivo MRS at 1.5 T usually lacks sensitivity to distinguish myo-inositol from glycine, 
both resonating at ~3.55 ppm (33), although the use of different echo times may 
enable distinction between these metabolites (34). Different levels of both myo­
inositol and glycine have been observed in glial tumours in vivo and in vitro 
(22,23,34,35). Interpretation of this data however is complicated because of the 
lower spectral resolution of MRS in vivo than in vitro. One has to consider also that 
biopsies and tumour extracts are not necessarily representative for a whole tumour 
as measured by in vivo MRS, and the tumour volume measured in vivo may partially 
contain normal brain tissue as well.
In the WHO tumour grading system oligodendrogliomas are divided into grade II 
(low grade) and grade III (high grade) tumours (1). In PET studies metabolic 
differences have been demonstrated between low grade and high grade 
oligodendrogliomas (36,37). In vivo MRS already showed to be useful in 
distinguishing the grades of other brain tumours (e.g. astrocytomas, 11,14,38-40). In 
the present study, none of the main metabolites analysed showed a statistically 
significant difference between low grade and high grade oligodendrogliomas,
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although borderline significance was reached for Ino (table 7.2, p<0.10). However, 
in tumours with high lipid resonances the levels of NAA and Glx might be 
overestimated, because contribution from lipid protons in unsaturated fatty acid 
chains (which resonate in the 2.0-2.6 ppm region) was not corrected for in the 
analysis. The lipids plus lactate signal did show a significant difference between 
high grade tumours and low grade oligodendrogliomas (table 7.2, p<0.01). This 
positive correlation between tumour grade and lipids plus lactate signal is also 
commonly found in other glial tumours. In high grade tumours mobile lipids 
accumulate in necrotic tissue, as was demonstrated by ex vivo MRS and histological 
investigations (41). The amount of mobile lipid signal was shown to correlate directly 
with histopathological grade (39). Both apoptosis, microscopic cellular necrosis and 
cell proliferation may contribute to the signal of mobile lipids (41-44). However, the 
observation that the relative level of all of the main metabolites was lower in high 
grade tumours than in low grade tumours (table 7.2) suggests a decreased 
cellularity in high grade tumours. In gliomas the Cho signal intensity has already 
been shown to correlate with local cellularity as measured by diffusion MRI (45).
Lipids plus lactate signal intensity as a marker for malignancy of oligodendrogliomas 
is relevant in both diagnosis and treatment planning. Grading of oligodendroglial 
tumours according to the WHO criteria has been shown to be of prognostic 
relevance and a significant predictor of survival (29,46). Furthermore, treatment of 
oligodendrogliomas may be deferred until there is clinical or radiological evidence of 
progression, unless patients have disabling symptoms or signs at presentation (2). 
In this respect, MRS could be used as a noninvasive tool for low grade 
oligodendrogliomas to monitor a development into higher malignancy of these 
tumours.
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Magnetic Resonance Imaging (MRI) and Magnetic Resonance Spectroscopy (MRS) 
techniques allow us to investigate patients with tumours in a noninvasive way. 
These techniques can be used not only for tumour identification, but also for tumour 
characterisation. In this thesis, MRI and MRS have been applied to investigate 
tumour physiology and metabolism in patients with tumours in the head-neck region, 
patients with oligodendrogliomas, and patients with meningiomas. Identification and 
characterisation of these tumours could assist in prediction of treatment response 
and selection of the best therapeutical option for these patients.
The biological and clinical background of the tumours studied in this thesis is 
described in chapter 1. Tumours often feature a more chaotic vascular architecture 
than normal tissue and a heterogeneous blood supply. This may result in local 
hypoxia and necrosis. Information on tumour physiology may aid not only to the 
characterisation of tumours, but also to treatment planning. Tumour blood flow for 
example is of fundamental importance to the efficacy of chemotherapy (drug 
delivery) and radiotherapy (oxygen supply).
The general principles of MR imaging and MR spectroscopy and their main 
applications as used in this thesis are summarised in chapter 2. Two of the central 
MR approaches to monitor physiological processes in tumours are dynamic contrast 
enhanced MRI and blood oxygen level dependent (BOLD) MRI. Dynamic contrast 
enhanced MRI can be applied to assess vascular parameters including tumour 
blood flow, vascular permeability, and blood volume. BOLD MRI can be used to 
assess changes in the blood oxygenation status. In chapter 3 these techniques are 
applied to study the physiology of squamous cell carcinomas of the larynx. The 
clinical application of BOLD MRI for the assessment of tumours was illustrated by 
showing the potential to predict treatment response to radiotherapy with 
hyperoxygenation.
A detailed description of the acquisition and analysis of dynamic contrast enhanced 
MRI data is presented in chapter 4. The MRI contrast agent Gadolinium-DTPA was 
administered by bolus injection and its effect was monitored in time by fast MR 
imaging. A simple algorithm was developed for automatic extraction of the arterial 
input function from the dynamic contrast enhanced MRI data. This arterial input 
function was used in the pixelwise pharmacokinetic determination of physiological 
vascular parameters in normal and tumour tissue. Maps were reconstructed to show 
the spatial distribution of parameter values. To test the reproducibility of the method 
eleven patients with different types of tumours were each measured twice, and the 
rate of contrast agent uptake in the tumour was calculated. The results show that 
normalising the dynamic contrast enhanced MRI data using individual coregistered 
arterial input functions, instead of one common arterial input function for all patients, 
substantially reduces the variation between successive measurements. It was
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concluded that the proposed method enables the reproducible assessment of 
contrast agent uptake rates in human tumours.
Both dynamic contrast enhanced MRI and BOLD MRI were used to assess the 
effects of breathing a hyperoxic hypercapnic gas mixture on blood oxygenation and 
vascularity of head and neck tumours, as described in chapter 5. For tumours in the 
head-neck region breathing carbogen and administration of nicotinamide has been 
shown to result in a significantly improved tumour response to accelerated 
radiotherapy (ARCON). This may be caused by improved tumour oxygenation, 
possibly intermediated by vascular effects. For this reason, both blood oxygenation 
and vascular effects of breathing a hyperoxic hypercapnic gas mixture (98% O2 + 
2% CO2) were assessed in patients with tumours in the head-neck region. Tumour 
vascularity and oxygenation were investigated by dynamic Gadolinium-DTPA 
contrast enhanced MRI and BOLD MRI respectively. Eleven patients with primary 
head and neck tumours were each measured twice; with and without breathing the 
hyperoxic hypercapnic gas mixture. BOLD MR imaging revealed a significant 
increase of the MRI time constant of transverse magnetisation decay (T2*) in the 
tumour during hypercapnic hyperoxygenation, which correlates to a decrease of the 
deoxyhaemoglobin concentration. No changes in overall tumour vascularity were 
observed, as measured by the Gadolinium-DTPA contrast agent uptake rate in the 
tumour. It was concluded that breathing a hyperoxic hypercapnic gas mixture 
improves tumour blood oxygenation in patients with head and neck tumours, which 
may contribute to the success of the ARCON therapy.
A similar MRI study investigating the effects of hyperoxygenation is described in 
chapter 6 for meningiomas. Because meningiomas tend to recur after (partial) 
surgical resection, radiotherapy is increasingly being applied for the treatment of 
these tumours. Radiation dose levels are limited however to avoid radiation damage 
to the surrounding normal tissue. The radiosensitivity of tumours can be improved 
by increasing tumour oxygen levels. In this study BOLD MRI was applied to 
investigate if breathing a hyperoxic hypercapnic gas mixture could improve the 
oxygenation of meningiomas. In addition, dynamic Gadolinium-DTPA contrast 
enhanced MRI was used to assess changes in tumour vascularity under hyperoxic 
hypercapnic conditions. Ten meningioma patients were each studied without and 
with breathing a gas mixture consisting of 2% CO2 and 98% O2. Values of T2* and 
the Gadolinium-DTPA uptake rate were calculated under both conditions. In six 
tumours a significant increase in the value of T2* in the tumour was found, 
suggesting an improved tumour blood oxygenation, which exceeded the effect in 
normal brain tissue. Contrarily, two tumours showed a significant T2* decrease. The 
change in T2* was found to correlate with both the Gadolinium-DTPA uptake rate 
and with the change in the Gadolinium-DTPA uptake rate. The overall effect of 
hypercapnic hyperoxia on meningiomas was suggested to be a balance between 
oxygenation and vascular effects. Improved oxygenation of blood entering the
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tumour may be counteracted by a reduction in tumour blood volume and flow. It was 
concluded that the proposed MRI protocol may assist in radiation treatment 
selection in patients with meningiomas.
In chapter 7 an MR spectroscopy study is described characterising brain tumours, in 
particular oligodendrogliomas. These tumours may not be distinguished easily from 
other brain tumours based on clinical presentation and MRI alone. Identification of 
oligodendrogliomas however may have therapeutical consequences, as they show a 
unique chemosensitivity. In this study oligodendrogliomas were characterised and 
identified by their metabolic profile as measured by 1H MR spectroscopy. Fifteen 
patients with oligodendroglial tumours (8 high grade oligodendrogliomas, 7 low 
grade oligodendrogliomas) underwent MRI and short echo time 1H MRS 
examinations. Five main metabolites found in brain MR spectra were quantified and 
expressed as ratios of tumour to contralateral white matter tissue. The level of lipids 
plus lactate was also assessed in the tumour. For comparison also six patients with 
a low grade astrocytoma were included in the study. In high grade 
oligodendrogliomas large resonances of lipids plus lactate were observed in 
contrast to low grade tumours. Thus, MRS could be used as a noninvasive tool for 
low grade oligodendrogliomas to monitor a development into higher malignancy of 
these tumours. Compared to white matter, the metabolic profile of 
oligodendrogliomas showed a decreased level of N-acetylaspartate and increased 
levels of choline containing compounds and glutamine plus glutamate. The level of 
glutamine plus glutamate was significantly higher in low grade oligodendrogliomas 
than in low grade astrocytomas and may serve as a metabolic marker in diagnosis 
and treatment planning.
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Met behulp van Magnetic Resonance Imaging (MRI) en Magnetic Resonance 
Spectroscopy (MRS) kunnen patiënten met tumoren op een niet-invasieve wijze 
bestudeerd worden. Deze technieken kunnen niet alleen gebruikt worden om 
tumoren te identificeren, maar ook om een tumor te karakteriseren. In dit proefschrift 
zijn MRI en MRS toegepast om de fysiologie en het metabolisme te onderzoeken 
van tumoren in het hoofd-hals gebied, meningiomen en oligodendrogliomen. 
Identificatie en karakterisering van deze tumoren kunnen bijdragen aan het 
voorspellen van de respons op een behandeling en de selectie van de beste 
behandelingsstrategie voor deze patiënten.
In hoofdstuk 1 staan de biologische en klinische achtergronden beschreven van de 
tumoren die bestudeerd zijn in dit proefschrift. In vergelijking met normaal weefsel 
hebben tumoren vaak een heterogene bloedvoorziening en is het bloedvatenstelsel 
minder goed geordend. Dit kan tot gevolg hebben dat er plaatselijk een tekort komt 
aan zuurstof (hypoxie) of dat cellen doodgaan (necrose). Dit soort informatie over 
een tumor kan belangrijk zijn voor de planning van therapie. Zo is de doorbloeding 
van een tumor van groot belang voor chemotherapie (toevoer van geneesmiddelen) 
en radiotherapie (toevoer van zuurstof).
Het algemene principe van MRI en MRS en de voor dit proefschrift belangrijkste 
toepassingen zijn samengevat in hoofdstuk 2. Om fysiologische processen in kaart 
te brengen zijn twee MRI methoden met name van belang: MRI waarbij de opname 
van contrastmiddel gemeten wordt in een tumor (dynamische contrast MRI) en MRI 
die gevoelig is voor deoxyhemoglobine in het bloed (blood oxygen level dependent, 
BOLD MRI). Met dynamische contrast MRI kunnen vasculaire- en weefsel- 
eigenschappen bestudeerd worden, zoals permeabiliteit van bloedvaten, 
bloedvolume en doorbloeding. BOLD MRI kan gebruikt worden om veranderingen in 
de oxygenatie van het bloed te onderzoeken. In hoofdstuk 3 worden deze 
technieken toegepast op plaveiselcelcarcinomen van de larynx. Ook wordt de 
potentie van BOLD MRI om de respons op radiotherapie te voorspellen toegelicht.
De methode van het opnemen en analyseren van gegevens bij dynamische contrast 
MRI is beschreven in hoofdstuk 4. Na intraveneuze toediening van het MRI 
contrastmiddel Gadolinium-DTPA werd de opname in tumoren anderhalve minuut 
lang gemeten. Het verloop van de concentratie Gadolinium-DTPA in de tijd in grote 
arteriën werd met behulp van een algoritme bepaald. Deze zogenaamde arteriële 
input functie was nodig om met een farmacokinetisch model de fysiologische 
parameters van normaal- en tumorweefsel te berekenen. Door dit voor elk pixel te 
doen konden er van deze parameters ook afbeeldingen gemaakt worden. Om de 
reproduceerbaarheid van de methode te testen werd van elf patiënten de 
opnamesnelheid van het contrastmiddel twee keer gemeten. De resultaten lieten 
zien dat de variatie tussen de twee metingen verminderde als de dynamische 
contrast MRI gegevens genormaliseerd werden met een individueel opgenomen
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arteriële input functie. De conclusie was dat de voorgestelde methode het mogelijk 
maakt om opname van contrastmiddel in tumoren op een reproduceerbare wijze te 
meten.
BOLD MRI en dynamische contrast MRI werden beide toegepast om de oxygenatie 
van het bloed en de vasculaire eigenschappen van tumoren in het hoofd-hals 
gebied te bestuderen. Hierbij ademden de patiënten een gasmengsel van 98% O2 
en 2% CO2 (hyperoxygenatie). Dit onderzoek staat beschreven in hoofdstuk 5. Er 
was al aangetoond dat de respons van tumoren in het hoofd-hals gebied op 
radiotherapie verbeterde als deze behandeling gecombineerd werd met toediening 
van nicotinamide en het ademen van carbogeen (ARCON). Dit zou verklaard 
kunnen worden door een toegenomen hoeveelheid zuurstof in de tumor. Daarom 
werden de vasculaire eigenschappen en de oxygenatie van het bloed in de tumor 
gemeten voor en tijdens hyperoxygenatie. Elf patiënten met tumoren in het hoofd­
hals gebied werden op deze wijze bestudeerd. BOLD MRI resultaten lieten een 
sterke toename van de MRI parameter T2* zien tijdens hyperoxygenatie, wat duidt 
op een afname van de hoeveelheid deoxyhemoglobine. Er werden geen 
veranderingen waargenomen in de snelheid van opname van het contrastmiddel. 
De conclusie was dat het ademen van het gasmengsel de oxygenatie van het bloed 
in de tumor verbetert bij patiënten met tumoren in het hoofd-hals gebied en dat dit 
mogelijk bijdraagt aan het succes van de ARCON therapie.
Een soortgelijke studie voor meningiomen staat beschreven in hoofdstuk 6. Omdat 
meningiomen vaak hernieuwde groei vertonen na (gedeeltelijke) operatieve 
verwijdering, wordt radiotherapie in toenemende mate toegepast. De hoeveelheid 
straling die gegeven kan worden is echter gelimiteerd om schade in het omliggende 
hersenweefsel te voorkomen. De gevoeligheid voor radiotherapie kan wel verbeterd 
worden door de hoeveelheid zuurstof in de tumor te vergroten. In deze studie werd 
BOLD MRI toegepast om de oxygenatie van het bloed in de tumor te meten voor en 
tijdens het ademen van een gasmengsel van 98% O2 en 2% CO2. Ook werd een 
dynamische contrast MRI uitgevoerd om veranderingen in de vasculaire 
eigenschappen van de tumor onder deze condities in kaart te brengen. Tien 
patiënten met meningiomen werden op deze wijze bestudeerd. In zes tumoren werd 
een sterke toename in T2* gevonden, wat duidt op een verbeterde oxygenatie van 
het bloed in de tumor. In twee tumoren werd echter een tegengesteld effect 
waargenomen. De verandering in T2* bleek te correleren met de verandering in de 
opnamesnelheid van het contrastmiddel. De conclusie was dat het effect van 
hyperoxygenatie op meningiomen een samenspel is van oxygenatie- en vasculaire 
effecten. Hoewel het bloed dat een tumor binnenstroomt meer zuurstof zal bevatten 
tijdens hyperoxygenatie, kan deze verbeterde oxygenatie weer tegengewerkt 
worden door een afname in het bloedvolume of de doorbloeding van de tumor. Het 
voorgestelde MRI protocol kan in individuele gevallen bijdragen tot de keuze wel of
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niet hyperoxygenatie toe te passen bij radiotherapeutische behandeling van deze 
tumoren.
In hoofdstuk 7 staat een MRS studie beschreven om hersentumoren te 
karakteriseren, in het bijzonder oligodendrogliomen. Deze tumoren kunnen niet 
gemakkelijk van andere hersentumoren onderscheiden worden op basis van de 
klinische symptomen en MRI beelden. De identificatie van oligodendrogliomen is 
echter belangrijk, omdat deze tumoren wel positief op chemotherapie reageren, 
terwijl andere gliale tumoren dat doorgaans niet doen. In deze studie werd het 
metabole profiel van vijftien patienten met oligodendrogliomen (8 hooggradige en 7 
laaggradige tumoren) gemeten met behulp van 1H MR spectroscopie. De vijf 
belangrijkste metabolieten die gewoonlijk gevonden worden in MR spectra van de 
hersenen werden geanalyseerd, evenals de hoeveelheid lipiden en lactaat. Om te 
kunnen vergelijken met andere tumoren werden ook zes patiënten met laaggradige 
astrocytomen opgenomen in de studie. In hooggradige oligodendrogliomen werd 
een hoge concentratie aan lipiden en lactaat waargenomen in tegenstelling tot 
laaggradige tumoren. Vergeleken met normaal hersenweefsel (witte stof) liet het 
metabole profiel van oligodendrogliomen een afname zien van N-acetylaspartaat en 
een toename van choline-verbindingen en glutamine plus glutamaat. De 
concentratie glutamine plus glutamaat was ook significant hoger in laaggradige 
oligodendrogliomen dan in laaggradige astrocytomen en zou zodoende gebruikt 
kunnen worden als metabole marker voor tumor diagnose en het plannen van 
therapie.
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Een vreemde avond -
DE BOMEN LIJKEN BOMEN 
EN HET GRAS IS GROEN
(W.J. van der Molen)
